http://jnci.oxfordjournals.org/content/99/11/847.full
<!DOCTYPE html
  PUBLIC "-//W3C//DTD XHTML 1.0 Strict//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-strict.dtd">
<html
      xmlns="http://www.w3.org/1999/xhtml"
      xml:lang="en"
      lang="en">
   <head>
      <meta http-equiv="Content-Type" content="text/html; charset=UTF-8" />
      <title>Cisplatin- Versus Carboplatin-Based Chemotherapy in First-Line Treatment of Advanced Non–Small-Cell Lung Cancer: An Individual
         Patient Data Meta-analysis 
      </title>
      <meta name="googlebot" content="NOODP" />
      <meta name="HW.ad-path" content="/cgi/content/full/99/11/847" />
      <meta content="/jnci/99/11/847.atom" name="HW.identifier" />
      <meta name="DC.Format" content="text/html" />
      <meta name="DC.Language" content="en" />
      <meta content="Cisplatin- Versus Carboplatin-Based Chemotherapy in First-Line Treatment of Advanced Non–Small-Cell Lung Cancer: An Individual Patient Data Meta-analysis"
            name="DC.Title" />
      <meta content="10.1093/jnci/djk196" name="DC.Identifier" />
      <meta content="2007-06-06" name="DC.Date" />
      <meta content="Oxford University Press" name="DC.Publisher" />
      <meta content="Andrea Ardizzoni" name="DC.Contributor" />
      <meta content="Luca Boni" name="DC.Contributor" />
      <meta content="Marcello Tiseo" name="DC.Contributor" />
      <meta content="Frank V. Fossella" name="DC.Contributor" />
      <meta content="Joan H. Schiller" name="DC.Contributor" />
      <meta content="Marianne Paesmans" name="DC.Contributor" />
      <meta content="Davorin Radosavljevic" name="DC.Contributor" />
      <meta content="Adriano Paccagnella" name="DC.Contributor" />
      <meta content="Petr Zatloukal" name="DC.Contributor" />
      <meta content="Paola Mazzanti" name="DC.Contributor" />
      <meta content="Donald Bisset" name="DC.Contributor" />
      <meta content="Rafael Rosell" name="DC.Contributor" />
      <meta content="Journal of the National Cancer Institute"
            name="citation_journal_title" />
      <meta content="JNCI J Natl Cancer Inst" name="citation_journal_abbrev" />
      <meta content="0027-8874" name="citation_issn" />
      <meta content="1460-2105" name="citation_issn" />
      <meta name="citation_author" content="Andrea Ardizzoni" />
      <meta name="citation_author" content="Luca Boni" />
      <meta name="citation_author" content="Marcello Tiseo" />
      <meta name="citation_author" content="Frank V. Fossella" />
      <meta name="citation_author" content="Joan H. Schiller" />
      <meta name="citation_author" content="Marianne Paesmans" />
      <meta name="citation_author" content="Davorin Radosavljevic" />
      <meta name="citation_author" content="Adriano Paccagnella" />
      <meta name="citation_author" content="Petr Zatloukal" />
      <meta name="citation_author" content="Paola Mazzanti" />
      <meta name="citation_author" content="Donald Bisset" />
      <meta name="citation_author" content="Rafael Rosell" />
      <meta content="Cisplatin- Versus Carboplatin-Based Chemotherapy in First-Line Treatment of Advanced Non–Small-Cell Lung Cancer: An Individual Patient Data Meta-analysis"
            name="citation_title" />
      <meta content="99" name="citation_volume" />
      <meta content="11" name="citation_issue" />
      <meta content="847" name="citation_firstpage" />
      <meta content="857" name="citation_lastpage" />
      <meta content="99/11/847" name="citation_id" />
      <meta content="99/11/847" name="citation_id_from_sass_path" />
      <meta content="jnci;99/11/847" name="citation_mjid" />
      <meta content="10.1093/jnci/djk196" name="citation_doi" />
      <meta content="http://jnci.oxfordjournals.org/content/99/11/847.abstract"
            name="citation_abstract_html_url" />
      <meta content="http://jnci.oxfordjournals.org/content/99/11/847.full"
            name="citation_fulltext_html_url" />
      <meta content="http://jnci.oxfordjournals.org/content/99/11/847.full.pdf"
            name="citation_pdf_url" />
      <meta content="/content/99/11.cover.gif" name="issue_cover_image" />
      <meta content="http://jnci.oxfordjournals.org/content/99/11/847"
            name="citation_public_url" />
      <meta content="17551145" name="citation_pmid" />
      <meta name="citation_section" content="Article" />
      <meta name="robots" content="noarchive,nofollow" />
      <meta name="googlebot" content="noarchive" />
      <link href="/content/99/11/838.short" rel="prev" />
      <link href="/content/99/11/858.short" rel="next" />
      <link rel="stylesheet" type="text/css" media="all" href="/shared/css/hw-global.css" />
      <link rel="stylesheet" type="text/css" media="print" href="/shared/css/hw-print.css" />
      <link rel="stylesheet" type="text/css" media="all"
            href="/local/css/hw-local-global.css" />
      <link rel="stylesheet" type="text/css" media="all"
            href="/publisher/css/hw-publisher-global.css" />
      <link rel="stylesheet" type="text/css" media="all"
            href="/publisher/css/hw-publisher-ac.css" />
      <link rel="stylesheet" type="text/css" media="all"
            href="/shared/css/hw-page-content.css" />
      <link rel="stylesheet" type="text/css" media="all"
            href="/shared/css/jquery.fancybox-1.3.4.css" />
      <link rel="stylesheet" type="text/css" media="all"
            href="/shared/css/hw-global-colexpand.css" />
      <link rel="stylesheet" type="text/css" media="all"
            href="/publisher/css/hw-publisher-page-content.css" /><script type="text/javascript" id="session-d29336306e1">var callbackToken='5378C25622D8400';</script><script type="text/javascript" id="session-d29336306e3">
                      var subCode='oupjournal_sub';
                    </script><script type="text/javascript">
            var gAuthTimeStamp = '2015-10-27T12:13:12.864-07:00';
            var gSessionId = 'gFGPJrCwWB21D3cex-XZZg';
            var gAuthzRequired = 'false';
            var gAuthnMethods1 = 'ip ip';
            var gAuthnMethods2 = 'ip,ip';
            var gAuthnIPs = '18.189.59.169,18.189.59.169';
            var gAuthnIndividuals = '';
            var gAuthnInstitutions = '10005282,10072538,10328193,100274300,10082403,05094000,10093227,153074108,10080507,21879000,10095822,10081742,10082405,10004595,10019502,10082401,07635000,10082404,06602000';
            </script><script type="text/javascript" src="/shared/js/jquery-min.js"></script><script type="text/javascript" src="/shared/js/fingerprint.js"></script><script type="text/javascript" src="/shared/js/hw-shared.js"></script><script type="text/javascript" src="/publisher/js/hw-publisher-site.js"></script><script type="text/javascript" src="/local/js/local-js-vars.js"></script><script type="text/javascript" src="/shared/js/pages/hw-content.js"></script><script type="text/javascript" src="/shared/js/fancybox/jquery.fancybox-1.3.4.js"></script><script type="text/javascript" src="/shared/js/fancybox/jquery.easing-1.3.pack.js"></script><script type="text/javascript"
              src="/shared/js/fancybox/jquery.mousewheel-3.0.4.pack.js"></script><script type="text/javascript" src="/shared/js/util/content.jquery.addVariantLink.js"></script><script type="text/javascript" src="/shared/js/util/hw-col-expand.js"></script><script type="text/javascript" src="/publisher/js/hw-publisher-modalwin-vars.js"></script><script type="text/javascript"
              src="/publisher/js/hw-publisher-article-dynamic-elements.js"></script><script type="text/javascript" src="/publisher/js/hw-publisher-content.js"></script><script type="text/javascript" src="/shared/js/util/hw-mathjax.js"></script><script type="text/x-mathjax-config">
          MathJax.Hub.Config({
              tex2jax: {
                inlineMath: [["$","$"],["\\(","\\)"]],
                processClass: "tex2jax_process|mathjax"
              }
            });
          MathJax.Hub.Queue(function() {
            gColTempResize = true;
            fixColHeights(1);
            gColTempResize = false;
          });
       </script><script type="text/javascript"
              src="http://cdn.mathjax.org/mathjax/latest/MathJax.js?config=TeX-AMS-MML_HTMLorMML"></script><script type="text/javascript">
	    
	    
	    
	    var siqDOI = encodeURIComponent("10.1093/jnci/djk196");
	    var siqIsOpenAccess = encodeURIComponent("");
	    var siqPubDate = encodeURIComponent("20070606");

	    if (siqDOI.length == 0) {
	        siqDOI = "UNKNOWN";
	    }
	    
	    
		
		
	    if (gAuthnIndividuals.length != 0) {
		if (gAuthnInstitutions.length != 0) {
		    authnEntity = encodeURIComponent(gAuthnIndividuals
		        + ',' + gAuthnInstitutions);
		} else {
		    authnEntity = encodeURIComponent(gAuthnIndividuals);
		}
	    } else {
	        authnEntity = encodeURIComponent(gAuthnInstitutions);
	    }

	    var commonString =
		'authSessionId=' + gSessionId + String.fromCharCode(0x26)
		+ 'authzRequired=' + gAuthzRequired + String.fromCharCode(0x26)
		+ 'authentication_method=' + encodeURIComponent(gAuthnMethods2) + String.fromCharCode(0x26)
		+ 'authnIPs=' + gAuthnIPs + String.fromCharCode(0x26)
		+ 'authnInstitutions=' + authnEntity;

		
		
		
		

	    var gPageId = "pageid-content";
	    var gVariant = "full-text";

	    
		// Not completely done
		var eventType = "full-text";
		var accessType;
		if (siqIsOpenAccess == 'true') {
		    accessType = 'SOA';
		} else {
		    accessType = 'subscription';
		}
		    
		var NTPT_PGEXTRA =
		    commonString + String.fromCharCode(0x26)
		    + 'event_type=' + eventType + String.fromCharCode(0x26)
		    + 'publication_date=' + siqPubDate + String.fromCharCode(0x26)
		    + 'access_type=' + accessType + String.fromCharCode(0x26)
		    + 'doi=' + siqDOI ;
		    
		

	    // alert("NTPT_PGEXTRA is " + NTPT_PGEXTRA);
	</script><link rel="stylesheet" type="text/css" media="all" href="/resource/css/hw20.css" />
      <link rel="stylesheet" type="text/css" media="all"
            href="/resource/css/h20-oup-header.css" />
      <link rel="stylesheet" type="text/css" media="all"
            href="/resource/css/h20-oup-footer.css" />
      <link rel="stylesheet" type="text/css" media="all"
            href="/resource/css/h20-oup-sidebars.css" />
      <link type="text/css" media="all" rel="stylesheet" href="/site/resource/jnci_h20.css" />
      <link rel="stylesheet" type="text/css" href="/resource/css/print.css" media="print" /><script type="text/javascript" src="/resource/js/main.js"></script><link rel="stylesheet" type="text/css" media="all"
            href="http://oi-underbar.ifactory.com/underbar/css/pf_oiunderbar.css" />
      <link rel="stylesheet" type="text/css" media="screen"
            href="http://gab.cookie.oup.com/aws-cookie/jquery.fancybox-1.3.4_1.css" /><script type="text/javascript" src="/resource/js/oup_ad_size.js"></script></head>
   <body class="general_page journal jnci">
      <div class="hw-gen-page pagetype-content hw-pub-id-article" id="pageid-content"
           itemscope="itemscope"
           itemtype="http://schema.org/ScholarlyArticle">
         <noscript>
            <p>We use cookies to enhance your experience on our website. By continuing to use our website, you are agreeing to our use of
               cookies. You can change your cookie settings at any time. <a href="http://global.oup.com/cookiepolicy/">Find out more</a></p>
         </noscript>
         
         
         <p class="hide">
            <a href="#content">Skip Navigation</a>
            
         </p>
         
         
         <div id="secondary_nav">
            <strong id="page_logo" title="Oxford Journals"><a href="http://www.oxfordjournals.org/"><span>Oxford Journals</span></a></strong>
            
            <ul>
               <li id="nav_contact_us" title="Contact Us"><a href="http://www.oxfordjournals.org/contact_us.html"><span>Contact Us</span></a></li>
               <li id="nav_my_basket" title="My Basket"><a href="https://secure.oxfordjournals.org/basket.html"><span>My Basket</span></a></li>
               <li id="nav_my_account" title="My Account"><a href="http://services.oxfordjournals.org/cgi/tslogin?url=http://www.oxfordjournals.org/service/Register"><span>My 
                        
                        Account</span></a></li>
            </ul>
            
         </div>
         
         
         <div id="header">
            
            <h1 id="page_title" title="JNCI J Natl Cancer Inst"><a href="/"><span>
                     JNCI J Natl Cancer Inst
                     </span></a></h1>
            
         </div>
         
         
         <div id="primary_nav">
            
            <ul>
               <li id="nav_about_this_journal" title="About This Journal">
                  <a href="http://www.oxfordjournals.org/jnci/about.html">
                     
                     <span>About This Journal</span>
                     </a>
                  
               </li>
               <li id="nav_contact_this_journal" title="Contact This Journal"><a href="/cgi/feedback/"><span>Contact This Journal</span></a></li>
               <li id="nav_subscriptions" title="Subscriptions">
                  <a href="http://www.oxfordjournals.org/jnci/access_purchase/buy_online.html">
                     
                     <span>Subscriptions</span>
                     </a>
                  
               </li>
               <li id="nav_current_issue" title="Current"><a href="/content/current"><span>View Current Issue (Volume 107 Issue 10 October 2015)</span></a></li>
               <li id="nav_archive" title="Archive"><a href="/content/by/year"><span>Archive</span></a></li>
               <li id="nav_search" title="Search"><a href="/search"><span>Search</span></a></li>
            </ul>
            
         </div>
         
         
         <div id="user_nav">
            
            <div class="header-ac-elements">
               
               <div id="authstring">
                  
                  <ul>
                     <li class="subscr-ref">Institution:  MIT Libraries</li>
                     <li class="no-left-border">
                        <a href="/login?uri=http%3A%2F%2Fjnci.oxfordjournals.org%2Fcontent%2F99%2F11%2F847.full">
                           Sign In as Personal Subscriber
                           </a>
                        
                     </li>
                  </ul>           
                  
               </div>   
               
            </div>
            
         </div>
         
         
         <ul id="site-breadcrumbs">
            <li class="first"><a href="http://services.oxfordjournals.org/cgi/tslogin?url=http%3A%2F%2Fwww.oxfordjournals.org">Oxford Journals</a></li>
            <li><span class="breadcrumb_subjects"><a href="http://www.oxfordjournals.org/subject/medicine/"
                     class="breadcrumb_subject">Medicine &amp; Health</a></span></li>
            <li><a href="/">JNCI J Natl Cancer Inst</a></li>
            <li><a href="/content/99/11.toc">
                  <span xmlns="" class="volume-value">Volume 99</span>
                  <span xmlns="" class="issue-value"> Issue 11</span></a></li>
            <li>Pp. <span class="slug-pages">
                  847-857.
                  </span></li>
         </ul>
         
         
         
         
         <div id="oas_top" class="ad_hidden">
            <iframe id="id_advertframe_top"
                    src="/resource/htmlfiles/advert.html?p=Top&amp;u=jnci.oxfordjournals.org/content/99/11/847.full"
                    width="0"
                    height="0"
                    frameborder="0"
                    scrolling="no"
                    class="resize_ad"></iframe>
            
         </div>
         
         
         <a name="content"></a>
         
         
         <div id="h20_page"></div>
         
         <div id="content-block">
            <div class="article fulltext-view" itemprop="articleBody"><span class="highwire-journal-article-marker-start"></span><h1 id="article-title-1" itemprop="headline">Cisplatin- Versus Carboplatin-Based Chemotherapy in First-Line Treatment of Advanced Non–Small-Cell Lung Cancer: An Individual
                  Patient Data Meta-analysis
               </h1>
               <div class="contributors">
                  <ol class="contributor-list" id="contrib-group-1">
                     <li class="contributor" id="contrib-1" itemprop="author" itemscope="itemscope"
                         itemtype="http://schema.org/Person"><span class="name" itemprop="name"><a class="name-search"
                              href="/search?author1=Andrea+Ardizzoni&amp;sortspec=date&amp;submit=Submit">Andrea Ardizzoni</a></span>, 
                     </li>
                     <li class="contributor" id="contrib-2" itemprop="author" itemscope="itemscope"
                         itemtype="http://schema.org/Person"><span class="name" itemprop="name"><a class="name-search"
                              href="/search?author1=Luca+Boni&amp;sortspec=date&amp;submit=Submit">Luca Boni</a></span>, 
                     </li>
                     <li class="contributor" id="contrib-3" itemprop="author" itemscope="itemscope"
                         itemtype="http://schema.org/Person"><span class="name" itemprop="name"><a class="name-search"
                              href="/search?author1=Marcello+Tiseo&amp;sortspec=date&amp;submit=Submit">Marcello Tiseo</a></span>, 
                     </li>
                     <li class="contributor" id="contrib-4" itemprop="author" itemscope="itemscope"
                         itemtype="http://schema.org/Person"><span class="name" itemprop="name"><a class="name-search"
                              href="/search?author1=Frank+V.+Fossella&amp;sortspec=date&amp;submit=Submit">Frank V. Fossella</a></span>, 
                     </li>
                     <li class="contributor" id="contrib-5" itemprop="author" itemscope="itemscope"
                         itemtype="http://schema.org/Person"><span class="name" itemprop="name"><a class="name-search"
                              href="/search?author1=Joan+H.+Schiller&amp;sortspec=date&amp;submit=Submit">Joan H. Schiller</a></span>, 
                     </li>
                     <li class="contributor" id="contrib-6" itemprop="author" itemscope="itemscope"
                         itemtype="http://schema.org/Person"><span class="name" itemprop="name"><a class="name-search"
                              href="/search?author1=Marianne+Paesmans&amp;sortspec=date&amp;submit=Submit">Marianne Paesmans</a></span>, 
                     </li>
                     <li class="contributor" id="contrib-7" itemprop="author" itemscope="itemscope"
                         itemtype="http://schema.org/Person"><span class="name" itemprop="name"><a class="name-search"
                              href="/search?author1=Davorin+Radosavljevic&amp;sortspec=date&amp;submit=Submit">Davorin Radosavljevic</a></span>, 
                     </li>
                     <li class="contributor" id="contrib-8" itemprop="author" itemscope="itemscope"
                         itemtype="http://schema.org/Person"><span class="name" itemprop="name"><a class="name-search"
                              href="/search?author1=Adriano+Paccagnella&amp;sortspec=date&amp;submit=Submit">Adriano Paccagnella</a></span>, 
                     </li>
                     <li class="contributor" id="contrib-9" itemprop="author" itemscope="itemscope"
                         itemtype="http://schema.org/Person"><span class="name" itemprop="name"><a class="name-search"
                              href="/search?author1=Petr+Zatloukal&amp;sortspec=date&amp;submit=Submit">Petr Zatloukal</a></span>, 
                     </li>
                     <li class="contributor" id="contrib-10" itemprop="author" itemscope="itemscope"
                         itemtype="http://schema.org/Person"><span class="name" itemprop="name"><a class="name-search"
                              href="/search?author1=Paola+Mazzanti&amp;sortspec=date&amp;submit=Submit">Paola Mazzanti</a></span>, 
                     </li>
                     <li class="contributor" id="contrib-11" itemprop="author" itemscope="itemscope"
                         itemtype="http://schema.org/Person"><span class="name" itemprop="name"><a class="name-search"
                              href="/search?author1=Donald+Bisset&amp;sortspec=date&amp;submit=Submit">Donald Bisset</a></span> and 
                     </li>
                     <li class="last" id="contrib-12"><span class="name"><a class="name-search"
                              href="/search?author1=Rafael+Rosell&amp;sortspec=date&amp;submit=Submit">Rafael Rosell</a></span></li>
                     <li class="on-behalf-of"> For the CISCA (CISplatin versus CArboplatin) Meta-analysis Group</li>
                  </ol>
                  <ol class="affiliation-list">
                     <li class="aff"><a id="aff-1" name="aff-1"></a><address><strong>Affiliations of authors</strong>: Division of Medical Oncology, University Hospital, Parma, Italy (AA, MT); Unit of Clinical Trials, National Institute for
                           Cancer Research, Genova, Italy (LB); Department of Thoracic/Head and Neck Medical Oncology, M.D. Anderson Cancer Center, Houston,
                           TX (FVF); Eastern Cooperative Oncology Group, Division of Hematology/Oncology, University of Texas Southwestern, Dallas, TX
                           (JHS); European Lung Cancer Working Party, Data Centre, Institut Jules Bordet, Bruxelles, Belgium (MP); Department of Medical
                           Oncology, Institute for Oncology and Radiology of Serbia, Belgrade, Serbia and Montenegro (DR); Gruppo di Studio Tumori Polmonari
                           del Veneto, Division of Medical Oncology, SS Giovanni e Paolo Hospital, Venezia, Italy (AP); Charles University and Institute
                           of Postgraduate Studies, Prague, Faculty Hospital Na Bulovce, Prague, Czech Republic (PZ); Division of Medical Oncology, Umberto
                           I University Hospital, Ancona, Italy (PM); Department of Oncology, Grampian University Hospitals, Aberdeen, UK (DB); Medical
                           Oncology Service, Catalan Institute of Oncology, Hospital Germans Trias I Pujol, Barcelona, Spain (RR)
                        </address>
                     </li>
                  </ol>
                  <ol class="corresp-list">
                     <li class="fn" id="corresp-1"><strong>Correspondence to:</strong><br /> Andrea Ardizzoni, MD, Division of Medical Oncology, University Hospital, Via Gramsci 14, 43100 Parma, Italy (e-mail: <span class="em-link"><span class="em-addr">aardizzoni{at}ao.pr.it</span></span>)
                     </li>
                  </ol>
                  <ul class="history-list">
                     <li xmlns:hwp="http://schema.highwire.org/Journal" class="received"
                         hwp:start="2006-10-17"><span class="received-label">Received </span>October 17, 2006.
                     </li>
                     <li xmlns:hwp="http://schema.highwire.org/Journal" class="rev-recd"
                         hwp:start="2007-03-28"><span class="rev-recd-label">Revision received </span>March 28, 2007.
                     </li>
                     <li xmlns:hwp="http://schema.highwire.org/Journal" class="accepted"
                         hwp:start="2007-04-27"><span class="accepted-label">Accepted </span>April 27, 2007.
                     </li>
                  </ul>
               </div>
               <div class="section abstract" id="abstract-1" itemprop="description">
                  <div class="section-nav">
                     <div class="nav-placeholder"> </div><a href="#sec-11" title="Materials and Methods" class="next-section-link"><span>Next Section</span></a></div>
                  <h2>Abstract</h2>
                  <div id="sec-1" class="subsection">
                     <p id="p-1"><strong>Background</strong> Because the efficacy of carboplatin and cisplatin in the treatment of advanced non–small-cell lung cancer (NSCLC) has not
                        been proven to be equivalent, an individual patient data meta-analysis comparing the two treatments was performed.
                     </p>
                  </div>
                  <div id="sec-2" class="subsection">
                     <p id="p-2"><strong>Methods</strong> Randomized trials comparing carboplatin to cisplatin in first-line treatment of advanced NSCLC were identified and their
                        electronic databases obtained. A general variance-based method was used to estimate the summary hazard ratios (HRs), odds
                        ratios (ORs), and their 95% confidence intervals (CIs) for mortality, objective response, and toxicity. Cochran's chi-square
                        test (<em>Q</em> test) was used to test for heterogeneity among trials, and the <em>I<sup> 2</sup></em> index, which expresses the proportion of variability of the results due to heterogeneity, was calculated. A random-effects
                        model that takes into account interstudy variation was also applied. All statistical tests were two-sided.
                     </p>
                  </div>
                  <div id="sec-3" class="subsection">
                     <p id="p-3"><strong>Results</strong> Nine trials that included a total of 2968 patients were analyzed; overall median follow-up was 1021 days. The objective response
                        rate was higher for patients treated with cisplatin than for patients treated with carboplatin (30% versus 24%, respectively;
                        OR = 1.37; 95% CI = 1.16 to 1.61; <em>P</em>&lt;.001). Carboplatin treatment was associated with a non–statistically significant increase in the hazard of mortality relative
                        to treatment with cisplatin (HR = 1.07; 95% CI = 0.99 to 1.15; <em>P</em> = .100). In patients with nonsquamous tumors and those treated with third-generation chemotherapy, carboplatin-based chemotherapy
                        was associated with a statistically significant increase in mortality (HR = 1.12; 95% CI = 1.01 to 1.23 and HR = 1.11; 95%
                        CI = 1.01 to 1.21, respectively). Cisplatin-based chemotherapy was associated with more severe nausea and vomiting and nephrotoxicity;
                        severe thrombocytopenia was more frequent during carboplatin-based chemotherapy.
                     </p>
                  </div>
                  <div id="sec-4" class="subsection">
                     <p id="p-4"><strong>Conclusions</strong> Our individual patient data meta-analysis suggests that cisplatin-based chemotherapy is slightly superior to carboplatin-based
                        chemotherapy in terms of response rate and, in certain subgroups, in prolonging survival without being associated with an
                        increase in severe toxic effects. Therefore, cisplatin-based third-generation regimens should remain the standard reference
                        for the treatment of selected patients with advanced-stage NSCLC and of those with earlier-stage disease.
                     </p>
                  </div>
               </div>
               <p id="p-5">
                  <div class="boxed-text" id="boxed-text-1">
                     <div id="sec-5" class="subsection">
                        <h4>Context and Caveats</h4>
                        <div id="sec-6" class="subsection">
                           <h5>Prior knowledge</h5>
                           <p id="p-6">Platinum-based chemotherapy leads to a small but statistically significant improvement in survival in patients with advanced
                              non–small-cell lung cancer. Carboplatin had largely replaced cisplatin as the platinum-containing drug used to treat this
                              disease because it was associated with a lower incidence of serious side effects. However, it was unclear whether the two
                              drugs had similar clinical efficacy in the treatment of non–small-cell lung cancer.
                           </p>
                        </div>
                        <div id="sec-7" class="subsection">
                           <h5>Study design</h5>
                           <p id="p-7">A meta-analysis of individual patient data from randomized controlled clinical trials that compared chemotherapy regimens
                              containing either cisplatin or carboplatin.
                           </p>
                        </div>
                        <div id="sec-8" class="subsection">
                           <h5>Contribution</h5>
                           <p id="p-8">This study presented evidence that cisplatin was more effective than carboplatin in patients treated with newer chemotherapy
                              regimens and in patients with nonsquamous tumors. The side effects associated with the two drugs in non–small-cell lung cancer
                              patients were clarified.
                           </p>
                        </div>
                        <div id="sec-9" class="subsection">
                           <h5>Limitations</h5>
                           <p id="p-9">The conclusions are based on a somewhat heterogeneous group of clinical trials, some of which were small.</p>
                        </div>
                        <div id="sec-10" class="subsection">
                           <h5>Implications</h5>
                           <p id="p-10">Cisplatin may well be preferable to carboplatin in non–small-cell lung cancer patients whose disease is at an early stage
                              and in those patients who have advanced disease with a relatively good prognosis.
                           </p>
                        </div>
                     </div>
                  </div>
               </p>
               <p id="p-11">Approximately one-third of all cancer-related deaths in Western countries are due to lung cancer. Non–small-cell lung cancer
                  (NSCLC) represents 75%–80% of lung cancer cases and accounts for approximately 1.2 million new cases worldwide each year (<a id="xref-ref-1-1" class="xref-bibr" href="#ref-1">1</a>). Disappointingly, the 5-year survival rate is only about 15%, due to the high rate of unresectable disease at diagnosis
                  and to the inability of chemotherapy to cure metastatic disease.
               </p>
               <p id="p-12">The majority of patients with NSCLC have advanced disease at diagnosis and are therefore potential candidates for systemic
                  therapy. Several prospective trials and meta-analyses were required to prove convincingly that chemotherapy leads to a small
                  but statistically significant improvement in survival when compared with best supportive care only. In the meta-analysis by
                  the Non–Small-Cell Lung Cancer Collaborative Group, a reduction in mortality (hazard ratio [HR] = 0.73) was observed with
                  an absolute improvement of 10% in 1-year survival when platinum-based chemotherapy was compared with best supportive care
                  (<a id="xref-ref-2-1" class="xref-bibr" href="#ref-2">2</a>). Furthermore, randomized studies of chemotherapy versus best supportive care have shown that chemotherapy reduces cancer-related
                  symptoms and does not compromise quality of life (<a id="xref-ref-3-1" class="xref-bibr" href="#ref-3">3</a>).
               </p>
               <p id="p-13">A number of recent randomized studies have demonstrated that the addition of platinum to any one of a number of other single
                  agents resulted in an improved outcome compared with the single agent alone and that the introduction of third-generation
                  drugs, such as gemcitabine, taxanes, and vinorelbine, in conjunction with platinum further improved chemotherapy results in
                  advanced NSCLC (<a id="xref-ref-4-1" class="xref-bibr" href="#ref-4">4</a>). On the basis of these data, recent American (<a id="xref-ref-5-1" class="xref-bibr" href="#ref-5">5</a>), Canadian (<a id="xref-ref-6-1" class="xref-bibr" href="#ref-6">6</a>), and European (<a id="xref-ref-7-1" class="xref-bibr" href="#ref-7">7</a>) guidelines for the treatment of advanced NSCLC recommend platinum-based third-generation chemotherapy doublets as standard
                  of care for first-line treatment.
               </p>
               <p id="p-14">Despite its pivotal role in NSCLC management, treatment with cisplatin is associated with a number of serious and unpleasant
                  side effects, including nausea and vomiting, myelosuppression, neurotoxicity, and renal function impairment, and it is burdened
                  by delivery problems, such as the need for prolonged hydration and hospitalization (<a id="xref-ref-8-1" class="xref-bibr" href="#ref-8">8</a>). To overcome these limitations, most clinicians now use the cisplatin analog carboplatin, which is associated with a lower
                  incidence of neurotoxicity, nephrotoxicity, and nausea and vomiting compared with cisplatin and does not require prolonged
                  hydration (<a id="xref-ref-9-1" class="xref-bibr" href="#ref-9">9</a>).
               </p>
               <p id="p-15">Although carboplatin and cisplatin have similar mechanisms of action and preclinical activity spectra, it is unclear whether
                  their clinical efficacy is the same for all tumor types. Although for some tumors, such as ovarian cancer, equivalent efficacy
                  has been convincingly proven, for others, such as germ cell and head–neck tumors, there is evidence for the inferiority of
                  carboplatin compared with cisplatin (<a id="xref-ref-10-1" class="xref-bibr" href="#ref-10">10</a>).
               </p>
               <p id="p-16">Nearly 3000 NSCLC patients were enrolled in several randomized trials to determine whether carboplatin or cisplatin is more
                  effective in treating NSCLC. The results from these trials were conflicting, and therefore, it is still debated whether it
                  is justified to replace cisplatin with carboplatin in standard practice (<a id="xref-ref-11-1" class="xref-bibr" href="#ref-11">11</a>–<a id="xref-ref-13-1" class="xref-bibr" href="#ref-13">13</a>). The use of carboplatin-based regimens is considered to be standard of care for NSCLC in the United States (<a id="xref-ref-14-1" class="xref-bibr" href="#ref-14">14</a>), whereas cisplatin-based regimens are generally preferred in Europe (<a id="xref-ref-15-1" class="xref-bibr" href="#ref-15">15</a>).
               </p>
               <p id="p-17">To compare efficacy of cisplatin and carboplatin in the first-line chemotherapy treatment of advanced NSCLC with sufficient
                  statistical power, we conducted an individual patient data meta-analysis (CISCA project [cisplatin versus carboplatin meta-analysis
                  in advanced NSCLC]) on all patients enrolled in randomized studies comparing the effectiveness of these two platinum agents.
               </p>
               <div class="section" id="sec-11">
                  <div class="section-nav"><a href="#abstract-1" title="Abstract" class="prev-section-link"><span>Previous Section</span></a><a href="#sec-16" title="Results" class="next-section-link"><span>Next Section</span></a></div>
                  <h2>Materials and Methods</h2>
                  <div id="sec-12" class="subsection">
                     <h3>Search for Trials</h3>
                     <p id="p-18">We searched all published (as English-language full paper or abstract) and unpublished randomized trials that compared cisplatin
                        with carboplatin in the first-line treatment of advanced NSCLC. Searches were conducted by 1) regular computer-aided searches
                        of MEDLINE or CANCERLIT literature databases; 2) examining reference lists of published trials, review articles, and bibliographies
                        of relevant oncology books; 3) searching meeting abstracts; 4) consulting the US National Cancer Institute (NCI) Physicians
                        Data Query Clinical Protocol; and 5) contacting individual trialists or cooperative research groups. For databases research,
                        the following strategies were used: “Cisplatin [MeSH] AND Carboplatin [MeSH] AND Carcinoma, Non-small-cell lung/drug therapy
                        [MeSH] AND Clinical trial [pt]” and “Cisplatin AND Carboplatin AND Non-small cell lung cancer.”
                     </p>
                  </div>
                  <div id="sec-13" class="subsection">
                     <h3>Selection of Trials</h3>
                     <p id="p-19">Trials had to fulfill the following inclusion criteria: 1) patients were randomly assigned to treatment; 2) cisplatin and
                        carboplatin were compared in first-line chemotherapy without confounding by additional agents or interventions (i.e., in the
                        combination chemotherapy, the control and experimental arms had to differ only by cisplatin or carboplatin component); and
                        3) only patients with diagnosis of NSCLC were included.
                     </p>
                  </div>
                  <div id="sec-14" class="subsection">
                     <h3>Individual Patient Data Collection</h3>
                     <p id="p-20">The computer files containing the individual patients records including study identification acronym, patient identification
                        number, date of birth, sex, performance status, histology, stage at random assignment, date of randomization, treatment arm,
                        total number of administered cycles, best overall response, worst toxicity (hematologic, nausea and vomiting, neurotoxicity,
                        or nephrotoxicity), date of last observation, and status at last observation were requested from the principal investigators.
                        To avoid potential bias, information for all randomly assigned patients, including those who had been excluded from the final
                        analysis, was required.
                     </p>
                     <p id="p-21">Data were collected and analyzed at the Trial Office of National Institute for Cancer Research of Genova, Italy. All data
                        received were checked to ensure both the accuracy of the meta-analysis database and the quality of randomization and follow-up.
                        The study coordinator of each trial had to resolve any computer-generated query. The study protocol was approved by the Ethical
                        Committee and Review Board of the coordinating institution.
                     </p>
                  </div>
                  <div id="sec-15" class="subsection">
                     <h3>Statistical Analysis</h3>
                     <p id="p-22">The primary endpoint in the meta-analysis was overall survival, defined as the time elapsing from random assignment until
                        death from any cause. Living patients were censored at the date of last follow-up. The secondary endpoints were overall response
                        rate, defined as the sum of partial and complete response rates (according to World Health Organization criteria), and toxicity,
                        which was graded according to NCI Common Toxicity Criteria (CTC).
                     </p>
                     <p id="p-23">All analyses were conducted on an intention-to-treat basis, and all randomly assigned patients were included in the analyses
                        according to the allocated treatment. A general variance-based method was used to estimate the summary hazard ratios (HRs),
                        odds ratios (ORs), and their 95% confidence intervals (CIs) (<a id="xref-ref-16-1" class="xref-bibr" href="#ref-16">16</a>,<a id="xref-ref-17-1" class="xref-bibr" href="#ref-17">17</a>). Ratios were uniformly expressed relative to patients who received cisplatin therapy. The global null hypothesis that the
                        treatment difference in all studies is equal to 0 was tested by comparing the <em>U</em> statistic with the chi-square distribution with 1 df (<a id="xref-ref-17-2" class="xref-bibr" href="#ref-17">17</a>). Cochran's chi-square test (<em>Q</em> test) was used to test for the presence of heterogeneity among trials (<a id="xref-ref-18-1" class="xref-bibr" href="#ref-18">18</a>). Moreover, the <em>I</em><sup> 2</sup> index, which expresses as a percentage the proportion of variability of the results due to heterogeneity as opposed to sampling
                        error, was calculated (<a id="xref-ref-19-1" class="xref-bibr" href="#ref-19">19</a>). Based on the statistical significance of the <em>Q</em> test, we applied a random-effects model, which allows the meta-analysis to take into account interstudy variation. In particular,
                        the random-effects survival model was implemented with a frequentist approach fitting a Cox model with a frailty term (<a id="xref-ref-20-1" class="xref-bibr" href="#ref-20">20</a>). The variance of the Gaussian random-effects distribution was based on an approximate restricted maximum likelihood estimation
                        (<a id="xref-ref-20-2" class="xref-bibr" href="#ref-20">20</a>). Median follow-up time was estimated by the reverse Kaplan–Meier method (<a id="xref-ref-21-1" class="xref-bibr" href="#ref-21">21</a>).
                     </p>
                     <p id="p-24">The following factors were identified in the protocol of the study to plan the subgroup analyses: age (&lt;65 versus ≥65 years),
                        stage of disease (IIIB versus IV), performance status (0–1 versus 2), and histology (squamous versus nonsquamous). In the
                        analyses, an additional variable (second- versus third-generation chemotherapy regimen) was considered, although it was not
                        previously specified, based on the results of two meta-analyses that used abstracted data (<a id="xref-ref-22-1" class="xref-bibr" href="#ref-22">22</a>,<a id="xref-ref-23-1" class="xref-bibr" href="#ref-23">23</a>). Before the subgroup analyses, regression models were used to evaluate the statistical significance of the interaction between
                        the treatment and the potential prognostic factors. These models included a Cox model stratified by trials, for time-to-event
                        outcomes, and a logistic regression model with trial indicator variables, for binary outcomes (<a id="xref-ref-24-1" class="xref-bibr" href="#ref-24">24</a>).
                     </p>
                     <p id="p-25">All statistical analyses were conducted with SAS for Windows version 9.1 (Cary, NC) and R (<a href="http://www.r-project.org">http://www.r-project.org</a>). All statistical tests were two-sided, and <em>P</em> values of .05 or less were considered to be statistically significant, except for the test for interaction; in this case,
                        due to the explanatory purpose of the analyses, a cutoff equal to .10 was chosen.
                     </p>
                  </div>
               </div>
               <div class="section" id="sec-16">
                  <div class="section-nav"><a href="#sec-11" title="Materials and Methods" class="prev-section-link"><span>Previous Section</span></a><a href="#sec-20" title="Discussion" class="next-section-link"><span>Next Section</span></a></div>
                  <h2>Results</h2>
                  <p id="p-26">Nine eligible trials (<a id="xref-ref-25-1" class="xref-bibr" href="#ref-25">25</a>–<a id="xref-ref-33-1" class="xref-bibr" href="#ref-33">33</a>) were identified, and the respective electronic data bases were obtained for all of them. The analysis was conducted on the
                     individual data of the 2968 patients with advanced NSCLC (stage IIIB–IV) enrolled in the nine trials and randomly assigned
                     to receive chemotherapy with cisplatin (1489 patients) or with carboplatin (1479 patients), respectively.
                  </p>
                  <p id="p-27">Of the nine trials, seven were randomized phase III trials (<a id="xref-ref-25-2" class="xref-bibr" href="#ref-25">25</a>,<a id="xref-ref-26-1" class="xref-bibr" href="#ref-26">26</a>,<a id="xref-ref-28-1" class="xref-bibr" href="#ref-28">28</a>–<a id="xref-ref-31-1" class="xref-bibr" href="#ref-31">31</a>,<a id="xref-ref-33-2" class="xref-bibr" href="#ref-33">33</a>), and the remaining two were randomized phase II trials (<a id="xref-ref-27-1" class="xref-bibr" href="#ref-27">27</a>,<a id="xref-ref-32-1" class="xref-bibr" href="#ref-32">32</a>). None was a placebo-controlled, double-blind trial. Three trials included second-generation chemotherapy regimens: etoposide
                     (<a id="xref-ref-25-3" class="xref-bibr" href="#ref-25">25</a>), mitomycin and vindesine (<a id="xref-ref-26-2" class="xref-bibr" href="#ref-26">26</a>), and mitomycin and vinblastine (<a id="xref-ref-33-3" class="xref-bibr" href="#ref-33">33</a>). Five investigated third-generation chemotherapy doublets: cisplatin or carboplatin with paclitaxel (<a id="xref-ref-28-2" class="xref-bibr" href="#ref-28">28</a>,<a id="xref-ref-29-1" class="xref-bibr" href="#ref-29">29</a>), docetaxel (<a id="xref-ref-31-2" class="xref-bibr" href="#ref-31">31</a>), or gemcitabine (<a id="xref-ref-30-1" class="xref-bibr" href="#ref-30">30</a>,<a id="xref-ref-32-2" class="xref-bibr" href="#ref-32">32</a>). One trial compared cisplatin and carboplatin when they were used in combination with tirapazamine (<a id="xref-ref-27-2" class="xref-bibr" href="#ref-27">27</a>). Two of the nine trials included other treatment arms, in addition to the two arms considered for the meta-analysis (<a id="xref-ref-29-2" class="xref-bibr" href="#ref-29">29</a>,<a id="xref-ref-31-3" class="xref-bibr" href="#ref-31">31</a>). In the Eastern Cooperative Oncology Group (ECOG) 1594 trial, cisplatin–gemcitabine and cisplatin–docetaxel combinations
                     were also studied (<a id="xref-ref-29-3" class="xref-bibr" href="#ref-29">29</a>), and in the TAX326 study, some patients were randomly assigned to a cisplatin–vinorelbine arm (<a id="xref-ref-31-4" class="xref-bibr" href="#ref-31">31</a>). Cisplatin dose was 75 mg/m<sup>2</sup> in three trials (<a id="xref-ref-27-3" class="xref-bibr" href="#ref-27">27</a>,<a id="xref-ref-29-4" class="xref-bibr" href="#ref-29">29</a>,<a id="xref-ref-31-5" class="xref-bibr" href="#ref-31">31</a>), 80 mg/m<sup>2</sup> in three others (<a id="xref-ref-28-3" class="xref-bibr" href="#ref-28">28</a>,<a id="xref-ref-30-2" class="xref-bibr" href="#ref-30">30</a>,<a id="xref-ref-32-3" class="xref-bibr" href="#ref-32">32</a>), 100 mg/m<sup>2</sup> in one trial (<a id="xref-ref-33-4" class="xref-bibr" href="#ref-33">33</a>), and 120 mg/m<sup>2</sup> in two (<a id="xref-ref-25-4" class="xref-bibr" href="#ref-25">25</a>,<a id="xref-ref-26-3" class="xref-bibr" href="#ref-26">26</a>). For carboplatin, the dose was expressed in mg/m<sup>2</sup> in three trials; the doses were 325 (<a id="xref-ref-25-5" class="xref-bibr" href="#ref-25">25</a>), 500 mg/m<sup>2</sup> (<a id="xref-ref-26-4" class="xref-bibr" href="#ref-26">26</a>), and 300 mg/m<sup>2</sup> (<a id="xref-ref-33-5" class="xref-bibr" href="#ref-33">33</a>). Carboplatin dose was expressed according to Calvert formula (<a id="xref-ref-34-1" class="xref-bibr" href="#ref-34">34</a>) as area under the curve (AUC) in the other six trials; the AUC equaled 6 in four studies (<a id="xref-ref-27-4" class="xref-bibr" href="#ref-27">27</a>–<a id="xref-ref-29-5" class="xref-bibr" href="#ref-29">29</a>,<a id="xref-ref-31-6" class="xref-bibr" href="#ref-31">31</a>), and 5 in the other two trials (<a id="xref-ref-30-3" class="xref-bibr" href="#ref-30">30</a>,<a id="xref-ref-32-4" class="xref-bibr" href="#ref-32">32</a>).
                  </p>
                  <p id="p-28">In the nine trials included in the meta-analysis, patient characteristics were well balanced between the cisplatin and carboplatin
                     treatments (<a id="xref-table-wrap-1-1" class="xref-table" href="#T1">Table 1</a>), such that overall the set of patients treated with cisplatin and those treated with carboplatin had the same median age
                     (60 years), proportion of males (76%), and proportion of patients with performance status between 0 and 1 (86%). The proportions
                     of patients with stage IV disease were 68% and 69% in the cisplatin and carboplatin arms, respectively, and the proportion
                     of patients with squamous histology was slightly more than one-third in both arms. A median of four cycles was administered
                     for both cisplatin (range 0–15) and carboplatin (range 0–22).
                  </p>
                  <div class="table pos-float" id="T1">
                     <div class="table-inline">
                        <div class="callout"><span>View this table:</span><ul class="callout-links">
                              <li><a href="847/T1.expansion.html">In this window</a></li>
                              <li><a class="in-nw" href="847/T1.expansion.html">In a new window</a></li>
                           </ul>
                        </div>
                     </div>
                     <div class="table-caption"><span class="table-label">Table 1</span> 
                        <p id="p-29" class="first-child">Characteristics of patients enrolled in the nine trials included in the meta-analysis*</p>
                        <div class="sb-div caption-clear"></div>
                     </div>
                  </div>
                  <div id="sec-17" class="subsection">
                     <h3>Survival</h3>
                     <p id="p-31">Survival data were available from all nine studies (<a id="xref-table-wrap-2-1" class="xref-table" href="#T2">Table 2</a>). The overall median follow-up was 1021 days. Cisplatin-treated patients had a median survival of 9.1 months and a 1-year
                        survival probability of 37%, while carboplatin-treated patients had a median survival of 8.4 months and a 1-year survival
                        probability of 34% (<a id="xref-fig-1-1" class="xref-fig" href="#F1">Fig. 1</a>). The risk of death was higher with carboplatin compared with cisplatin, although the difference was not statistically significant
                        (HR = 1.07, 95% CI = 0.99 to 1.15, <em>P</em> = .100) (<a id="xref-fig-2-1" class="xref-fig" href="#F2">Fig. 2</a>). Moreover, there was statistically significant heterogeneity between treatment effects on mortality among the trials (<em>Q</em> test = 17.03, <em>P</em> = .030), and the <em>I <sup>2</sup></em> index indicated that 52% of the variability across trials was due to heterogeneity rather than chance. The random-effects
                        survival model gave an estimated value of the hazard ratio of mortality equal to 1.08 (95% CI = 1.00 to 1.16, <em>P</em> = .063).
                     </p>
                     <div class="table pos-float" id="T2">
                        <div class="table-inline">
                           <div class="callout"><span>View this table:</span><ul class="callout-links">
                                 <li><a href="847/T2.expansion.html">In this window</a></li>
                                 <li><a class="in-nw" href="847/T2.expansion.html">In a new window</a></li>
                              </ul>
                           </div>
                        </div>
                        <div class="table-caption"><span class="table-label">Table 2</span> 
                           <p id="p-32" class="first-child">Survival in the nine trials included in the meta-analysis*</p>
                           <div class="sb-div caption-clear"></div>
                        </div>
                     </div>
                     <div id="F1" class="fig pos-float odd">
                        <div class="fig-inline"><a href="847/F1.expansion.html"><img alt="Fig. 1" src="847/F1.small.gif" /></a><div class="callout"><span>View larger version:</span><ul class="callout-links">
                                 <li><a href="847/F1.expansion.html">In this window</a></li>
                                 <li><a class="in-nw" href="847/F1.expansion.html">In a new window</a></li>
                              </ul>
                              <ul class="fig-services">
                                 <li class="ppt-link"><a href="/powerpoint/99/11/847/F1">Download as PowerPoint Slide</a></li>
                              </ul>
                           </div>
                        </div>
                        <div class="fig-caption"><span class="fig-label">Fig. 1</span> 
                           <p id="p-36" class="first-child">Kaplan–Meier <strong>curves</strong> and <strong>error bars</strong> showing 95% confidence intervals of overall survival for cisplatin- and carboplatin-based chemotherapies.
                           </p>
                           <div class="sb-div caption-clear"></div>
                        </div>
                     </div>
                     <div id="F2" class="fig pos-float odd">
                        <div class="fig-inline"><a href="847/F2.expansion.html"><img alt="Fig. 2" src="847/F2.small.gif" /></a><div class="callout"><span>View larger version:</span><ul class="callout-links">
                                 <li><a href="847/F2.expansion.html">In this window</a></li>
                                 <li><a class="in-nw" href="847/F2.expansion.html">In a new window</a></li>
                              </ul>
                              <ul class="fig-services">
                                 <li class="ppt-link"><a href="/powerpoint/99/11/847/F2">Download as PowerPoint Slide</a></li>
                              </ul>
                           </div>
                        </div>
                        <div class="fig-caption"><span class="fig-label">Fig. 2</span> 
                           <p id="p-37" class="first-child">Overall survival of carboplatin- versus cisplatin-based chemotherapy. To describe the effect of carboplatin on mortality,
                              the log-rank statistic (the observed minus the expected number of deaths) and its variance were computed for each trial. Combining
                              these statistics, the event rate ratios of all trials and their weighted average were calculated with 95% confidence intervals
                              (CIs). The test statistics <em>U</em> and <em>Q</em> were used for hypothesis testing about treatment difference and presence of heterogeneity across studies, respectively. The
                              summary hazard ratio was 1.07 (95% CI = 0.99 to 1.15, <em>P</em> = .100).
                           </p>
                           <div class="sb-div caption-clear"></div>
                        </div>
                     </div>
                     <p id="p-38">The same test for heterogeneity was performed after omitting the study by Jelic at al. (<a id="xref-ref-26-7" class="xref-bibr" href="#ref-26">26</a>), the only one showing a statistically significant advantage of carboplatin over cisplatin. With this omission, the result
                        of the <em>Q</em> test was not statistically significant (<em>P</em> = .418), and the value of <em>I<sup> 2</sup></em> index decreased to 1%, indicating that most of heterogeneity in the meta-analysis was related to this single study.
                     </p>
                     <p id="p-39">In the subgroup analyses (these included all nine studies) according to age (&lt;65 versus ≥65 years), stage of disease (IIIB
                        versus IV), performance status (0–1 versus 2), histology (squamous versus nonsquamous), and type of chemotherapy regimen (second-
                        versus third-generation), the test for interaction between the treatment and the different variables reached statistical significance
                        for histology and for the type of regimen (<em>P</em> = .098 and <em>P</em> = .093, respectively) (<a id="xref-fig-3-1" class="xref-fig" href="#F3">Fig. 3</a>). In the different subgroups, we calculated the hazard ratio for mortality from all causes for patients treated with carboplatin
                        relative to those treated with cisplatin. Based on these analyses, the hazard ratio for mortality in patients with nonsquamous
                        NSCLC was 1.12 (95% CI = 1.01 to 1.23), whereas in the subgroup with squamous histology, it was 0.97 (95% CI = 0.85 to 1.10).
                        The hazard ratios for mortality were 0.94 (95% CI = 0.80 to 1.11) and 1.11 (95% CI = 1.01 to 1.21) in the subgroups of patients
                        treated with second- and third-generation regimens, respectively. Third-generation regimens were administered to 2330 patients,
                        80% of the total population.
                     </p>
                     <div id="F3" class="fig pos-float odd">
                        <div class="fig-inline"><a href="847/F3.expansion.html"><img alt="Fig. 3" src="847/F3.small.gif" /></a><div class="callout"><span>View larger version:</span><ul class="callout-links">
                                 <li><a href="847/F3.expansion.html">In this window</a></li>
                                 <li><a class="in-nw" href="847/F3.expansion.html">In a new window</a></li>
                              </ul>
                              <ul class="fig-services">
                                 <li class="ppt-link"><a href="/powerpoint/99/11/847/F3">Download as PowerPoint Slide</a></li>
                              </ul>
                           </div>
                        </div>
                        <div class="fig-caption"><span class="fig-label">Fig. 3</span> 
                           <p id="p-40" class="first-child"> Hazard ratios for mortality and their 95% confidence intervals of carboplatin- versus cisplatin-based chemotherapy for each
                              of the patient subgroups examined.
                           </p>
                           <div class="sb-div caption-clear"></div>
                        </div>
                     </div>
                  </div>
                  <div id="sec-18" class="subsection">
                     <h3>Response Rate</h3>
                     <p id="p-41">Data about objective response were available for all nine studies (<a id="xref-table-wrap-3-1" class="xref-table" href="#T3">Table 3</a>). Overall, 2669 patients, 1326 treated with cisplatin and 1343 with carboplatin, were assessable for response. (According
                        to the intention-to-treat principle, nonassessable patients were considered as nonresponders.) The response rates (complete
                        plus partial responses according to the World Health Organization criteria) were 30% for cisplatin and 24% for carboplatin,
                        respectively, with an odds ratio for nonresponse (among patients treated with carboplatin versus those treated with cisplatin)
                        of 1.37 (95% CI = 1.16 to 1.61; <em>P</em>&lt;.001) (<a id="xref-fig-4-1" class="xref-fig" href="#F4">Fig. 4</a>). The result of the test for heterogeneity among the studies was not statistically significant (<em>Q</em> test = 4.13; <em>P</em> = .845), and the <em>I<sup> 2</sup></em> index (0%) indicated that variability across trials was due to chance rather than heterogeneity.
                     </p>
                     <div class="table pos-float" id="T3">
                        <div class="table-inline">
                           <div class="callout"><span>View this table:</span><ul class="callout-links">
                                 <li><a href="847/T3.expansion.html">In this window</a></li>
                                 <li><a class="in-nw" href="847/T3.expansion.html">In a new window</a></li>
                              </ul>
                           </div>
                        </div>
                        <div class="table-caption"><span class="table-label">Table 3</span> 
                           <p id="p-42" class="first-child">Response rate in the nine trials included in the meta-analysis*</p>
                           <div class="sb-div caption-clear"></div>
                        </div>
                     </div>
                     <div id="F4" class="fig pos-float odd">
                        <div class="fig-inline"><a href="847/F4.expansion.html"><img alt="Fig. 4" src="847/F4.small.gif" /></a><div class="callout"><span>View larger version:</span><ul class="callout-links">
                                 <li><a href="847/F4.expansion.html">In this window</a></li>
                                 <li><a class="in-nw" href="847/F4.expansion.html">In a new window</a></li>
                              </ul>
                              <ul class="fig-services">
                                 <li class="ppt-link"><a href="/powerpoint/99/11/847/F4">Download as PowerPoint Slide</a></li>
                              </ul>
                           </div>
                        </div>
                        <div class="fig-caption"><span class="fig-label">Fig. 4</span> 
                           <p id="p-45" class="first-child">Response rate of carboplatin- versus cisplatin-based chemotherapy. To describe effect of carboplatin on objective response,
                              the observed minus the expected number of nonresponder patient statistic and its variance was computed for each trial. Combining
                              these statistics, the odds ratios of the trials and their weighted average were calculated with 95% confidence intervals (CIs).
                              The test statistics <em>U</em> and <em>Q</em> were used for hypothesis testing about treatment difference and presence of heterogeneity across studies, respectively. The
                              summary odds ratio was 1.37 (95% CI = 1.16 to 1.61, <em>P</em>&lt;.001).
                           </p>
                           <div class="sb-div caption-clear"></div>
                        </div>
                     </div>
                     <p id="p-46">In the subgroup analyses (these included all nine studies) according to age (&lt;65 versus ≥65 years), stage of disease (IIIB
                        versus IV), performance status (0–1 versus 2), histology (squamous versus nonsquamous), and type of chemotherapy regimen (second-
                        versus third-generation), the result of the interaction test between the treatment and the different variables was statistically
                        significant only when patients were categorized according to histology (<em>P</em> = .046). The odds ratio was 1.58 (95% CI = 1.27 to 1.97) in the subgroup of the patients with nonsquamous histology, whereas
                        it was 1.10 (95% CI = 0.85 to 1.43) in the subgroup with squamous histology.
                     </p>
                  </div>
                  <div id="sec-19" class="subsection">
                     <h3>Toxicity</h3>
                     <p id="p-47">Data as to the frequency of NCI-CTC grade 3–4 hematologic and nonhematologic toxic effects were available for eight of the
                        nine studies. Patients treated with carboplatin were more likely to experience thrombocytopenia compared with patients treated
                        with cisplatin (OR = 2.27, 95% CI = 1.71 to 3.01, <em>P</em>&lt;.001), whereas the frequencies of leucopenia (OR = 0.96, 95% CI = 0.81 to 1.14, <em>P</em> = .644), neutropenia (OR = 0.95, 95% CI = 0.80 to 1.12, <em>P</em> = .520), and anemia (OR = 1.10, 95% CI = 0.87 to 1.40, <em>P</em> = .424) were the same in those treated with cisplatin compared with those who received carboplatin (<a id="xref-table-wrap-4-1" class="xref-table" href="#T4">Table 4</a>). Cisplatin-based chemotherapy caused more nausea and vomiting than that based on carboplatin (OR = 0.42, 95% CI = 0.33 to
                        0.53, <em>P</em>&lt;.001) and renal toxicity (OR = 0.37, 95% CI = 0.15 to 0.88, <em>P</em> = .018). The incidence of neurotoxicity was not different in the two treatments groups (OR = 0.96, 95% CI = 0.75 to 1.23,
                        <em>P</em> = .758) (<a id="xref-table-wrap-5-1" class="xref-table" href="#T5">Table 5</a>).
                     </p>
                     <div class="table pos-float" id="T4">
                        <div class="table-inline">
                           <div class="callout"><span>View this table:</span><ul class="callout-links">
                                 <li><a href="847/T4.expansion.html">In this window</a></li>
                                 <li><a class="in-nw" href="847/T4.expansion.html">In a new window</a></li>
                              </ul>
                           </div>
                        </div>
                        <div class="table-caption"><span class="table-label">Table 4</span> 
                           <p id="p-48" class="first-child">Grade 3–4 (according to National Cancer Institute Common Toxicity Criteria) hematologic toxicity in eight of the nine trials
                              included in the meta-analysis*
                           </p>
                           <div class="sb-div caption-clear"></div>
                        </div>
                     </div>
                     <div class="table pos-float" id="T5">
                        <div class="table-inline">
                           <div class="callout"><span>View this table:</span><ul class="callout-links">
                                 <li><a href="847/T5.expansion.html">In this window</a></li>
                                 <li><a class="in-nw" href="847/T5.expansion.html">In a new window</a></li>
                              </ul>
                           </div>
                        </div>
                        <div class="table-caption"><span class="table-label">Table 5</span> 
                           <p id="p-52" class="first-child">Grade 3–4 (according to National Cancer Institute Common Toxicity Criteria) nonhematologic (nausea and vomiting, neurotoxicity,
                              and nephrotoxicity) toxicity in eight of the nine trials included in the meta-analysis*
                           </p>
                           <div class="sb-div caption-clear"></div>
                        </div>
                     </div>
                  </div>
               </div>
               <div class="section" id="sec-20">
                  <div class="section-nav"><a href="#sec-16" title="Results" class="prev-section-link"><span>Previous Section</span></a><a href="#fn-group-1" title="Footnotes" class="next-section-link"><span>Next Section</span></a></div>
                  <h2>Discussion</h2>
                  <p id="p-56">The results of this meta-analysis provide evidence that carboplatin-based combination chemotherapy is inferior to therapy
                     based on cisplatin in terms of the rate of objective response (OR for no response = 1.37, 95% CI = 1.16 to 1.61, <em>P</em>&lt;.001). Carboplatin-based chemotherapy appeared slightly less effective in prolonging survival, although overall the difference
                     was not statistically significant (HR of death = 1.07, 95% CI = 0.99 to 1.15, <em>P</em> = .100). However, when the analysis was restricted to the 2330 patients who were treated with third-generation platinum-based
                     regimens in more recent trials, treatment with cisplatin was associated with a statistically significant improvement in survival
                     compared with treatment based on carboplatin (HR of mortality with carboplatin relative to cisplatin = 1.11, 95% CI = 1.01
                     to 1.21). Similarly, when the analysis was restricted to patients with nonsquamous histology, treatment with cisplatin was
                     superior, in terms of survival, to treatment with carboplatin (HR = 1.12, 95% CI = 1.01 to 1.23).
                  </p>
                  <p id="p-57">The most likely explanation for the achievement of statistical significance in the third-generation chemotherapy and the nonsquamous
                     histology subgroups is that heterogeneity was eliminated in the subgroup analysis. In the analyses of those patients with
                     nonsquamous NSCLC and those who received third-generation chemotherapies, the trial reported by Jelic et al. (<a id="xref-ref-26-11" class="xref-bibr" href="#ref-26">26</a>) was not included because it was restricted to patients with squamous histology and it used a second-generation regimen.
                     This study from Serbia, which is the only one that showed statistically significant superiority of carboplatin, was the source
                     of most of the heterogeneity in the meta-analysis; when it was excluded, the test for heterogeneity did not reach statistical
                     significance. Why carboplatin was more effective than cisplatin in the Serbian study, in contrast to the results in most of
                     the other trials, is unknown. However, the patient population (it was younger, had a higher percentage of males and a higher
                     percentage of stage III cancers than the other studies, and was restricted to patients with squamous histology) and the higher
                     carboplatin dose [500 versus 325 (<a id="xref-ref-25-9" class="xref-bibr" href="#ref-25">25</a>) or 300 mg/m<sup>2</sup> (<a id="xref-ref-33-11" class="xref-bibr" href="#ref-33">33</a>)] used are factors that may account for this discrepancy. In the remaining eight studies, patient characteristics were very
                     similar. Five of the studies (<a id="xref-ref-25-10" class="xref-bibr" href="#ref-25">25</a>,<a id="xref-ref-28-9" class="xref-bibr" href="#ref-28">28</a>,<a id="xref-ref-31-12" class="xref-bibr" href="#ref-31">31</a>–<a id="xref-ref-33-12" class="xref-bibr" href="#ref-33">33</a>) showed survival trends in favor of cisplatin, and survival was statistically significantly longer in two of the five (<a id="xref-ref-28-10" class="xref-bibr" href="#ref-28">28</a>,<a id="xref-ref-31-13" class="xref-bibr" href="#ref-31">31</a>). The small study reported by Bisset et al. (<a id="xref-ref-27-10" class="xref-bibr" href="#ref-27">27</a>) showed a survival trend in favor of carboplatin. However, this trial enrolled only 41 patients and combined the platinum
                     agents with a nonclassical anticancer drug, tirapazamine, which by itself is not active against NSCLC.
                  </p>
                  <p id="p-58">Most of the evidence for the equivalence of carboplatin and cisplatin in terms of survival comes from the ECOG 1594 study
                     (<a id="xref-ref-29-11" class="xref-bibr" href="#ref-29">29</a>). In that four-arm study, 1207 patients were randomly allocated to receive the four most commonly used platinum-based regimens.
                     Among these, 602 patients were randomly assigned to receive cisplatin (75 mg/m<sup>2</sup> on day 2) combined with paclitaxel (135 mg/m<sup>2</sup> administered for a 24-hour period on day 1) every 3 weeks or carboplatin (AUC 6 on day 1) combined with paclitaxel (225 mg/m<sup>2</sup> for 3-hour period on day 1) every 3 weeks. The different doses and schedules of paclitaxel used in this study may represent
                     a possible bias for the comparison between cisplatin and carboplatin. Although the 135 mg/m<sup>2</sup> 24-hour infusion and the 225 mg/m<sup>2</sup> 3-hour infusion are supposed to have a comparable efficacy, to our knowledge, no formal clinical comparison between the two
                     schedules in patients with NSCLC has been reported. The ECOG 1594 study was designed to detect superiority in median survival
                     of 33% in each of the three experimental arms (including the carboplatin–paclitaxel arm) compared with cisplatin–paclitaxel
                     (the standard reference arm). Based on the results of ECOG 1594, superiority of the carboplatin–paclitaxel arm was excluded;
                     however, because the trial was not designed as a noninferiority trial, no conclusion can be drawn about equivalence of the
                     two regimens.
                  </p>
                  <p id="p-59">Another minor bias of this meta-analysis is related to the different doses of cisplatin and carboplatin used in trials that
                     we analyzed. Cisplatin dose ranged from 75 to 120 mg/m<sup>2</sup>, and carboplatin dose was either based on body surface (ranging from 300 to 500 mg/m<sup>2</sup>) or on AUC (ranging from 5 to 6). However, the platinum dose was always equivalent in the two arms of each study, and it
                     was rather homogenous in those studies in which third-generation treatments were given (cisplatin dose range = 75–80 mg/m<sup>2</sup> and carboplatin dose range = AUC 5–6). No evidence to date exists of a dose–response effect associated with platinum agents
                     within the range of the doses used in these studies. Therefore, it is unlikely that these minor differences in platinum doses
                     affected our findings.
                  </p>
                  <p id="p-60">Although the spectrum of toxicity of the two platinum agents was different, the superiority of cisplatin over carboplatin
                     was not achieved at the cost of a statistically significant increase in the incidence of severe side effects. Carboplatin-based
                     regimens were associated with more cases of thrombocytopenia of grade 3–4 (12% versus 6%, <em>P</em>&lt;.001). Cisplatin-based therapies were associated with more grade 3–4 nausea and vomiting (18% versus 8%; <em>P</em>&lt;.001) and nephrotoxicity (1.5% versus 0.5%, <em>P</em> = .018). It is likely that with the recent introduction of newer and more effective antiemetic agents (<a id="xref-ref-35-1" class="xref-bibr" href="#ref-35">35</a>), the 10% higher incidence of severe nausea and vomiting associated with intermediate- to high-dose cisplatin can be ameliorated
                     further. There was no difference in the rates of neurotoxicity in patients treated with cisplatin compared to those treated
                     with carboplatin.
                  </p>
                  <p id="p-61">Overall, quality of life could not be assessed in our study because only a minority of studies included in the meta-analysis
                     analyzed this endpoint. However, in the three studies where a formal quality of life assessment was prospectively performed,
                     there was no statistically significant difference in quality of life that could be attributed to treatment (<a id="xref-ref-28-11" class="xref-bibr" href="#ref-28">28</a>,<a id="xref-ref-31-14" class="xref-bibr" href="#ref-31">31</a>,<a id="xref-ref-33-13" class="xref-bibr" href="#ref-33">33</a>).
                  </p>
                  <p id="p-62">Our results are consistent with those of three other meta-analyses that compared carboplatin and cisplatin in NSCLC treatment
                     and analyzed only published data (<a id="xref-ref-22-2" class="xref-bibr" href="#ref-22">22</a>,<a id="xref-ref-23-2" class="xref-bibr" href="#ref-23">23</a>,<a id="xref-ref-36-1" class="xref-bibr" href="#ref-36">36</a>). In the only meta-analysis reported in full, Hotta et al. (<a id="xref-ref-22-3" class="xref-bibr" href="#ref-22">22</a>) found, based on analysis of eight trials, that cisplatin-based chemotherapy was superior in terms of response rate (OR =
                     1.36, 95% CI = 1.15 to 1.61, <em>P</em>&lt;.001) but not in terms of survival (HR = 1.050, 95% CI = 0.907 to 1.216, <em>P</em> = .515). In this meta-analysis as well, a statistically significant survival advantage for cisplatin was observed in the
                     subgroup of third-generation regimens (HR = 1.106, 95% CI = 1.005 to 1.218, <em>P</em> = .039).
                  </p>
                  <p id="p-63">Our meta-analysis was conducted on individual patient data and, therefore, it permits us to draw more definite conclusions
                     than previous analyses, according to the reasons given by Piedbois and Buyse (<a id="xref-ref-37-1" class="xref-bibr" href="#ref-37">37</a>). In fact, in contrast to meta-analysis based on abstracted data, individual patient data meta-analysis allows the investigator
                     to evaluate the reliability of the randomization methods, check the trial data, repeat the original analyses (or perform other
                     ones), and update the patients’ outcomes.
                  </p>
                  <p id="p-64">Given the palliative nature of chemotherapy treatment in advanced NSCLC and the unquestionable practical advantage of carboplatin
                     in terms of ease of administration, it could be argued that the small benefit achieved with cisplatin relative to carboplatin
                     does not justify its preferential use in clinical practice. However, all the progress in the treatment of advanced NSCLC has
                     been made in small increments. Particularly, if one considers that the use of platinum-based combination chemotherapy as opposed
                     to no chemotherapy at all led to only a 27% reduction in the hazard of mortality (<a id="xref-ref-2-2" class="xref-bibr" href="#ref-2">2</a>), the benefit from substituting of one platinum agent for another might not be expected to be higher than that observed in
                     this meta-analysis. Other drug substitutions, such as the introduction of third-generation agents, have gained success in
                     clinical practice despite a similarly small benefit (<a id="xref-ref-38-1" class="xref-bibr" href="#ref-38">38</a>). If the results of this meta-analysis may still support the use of carboplatin-based regimens in the palliative treatment
                     of patients with very advanced disease and/or poor performance status, cisplatin regimens may well be preferable in patients
                     whose performance status is good and whose disease is less advanced (i.e., oligometastatic stage IV and stage III diseases).
                     Furthermore, the recent results of the Cancer and Leukemia Group B (CALGB) 9633 adjuvant trial, which was performed in patients
                     with completely resected stage IB NSCLC and, unlike other recent adjuvant trials (<a id="xref-ref-39-1" class="xref-bibr" href="#ref-39">39</a>), showed no benefit of carboplatin–paclitaxel chemotherapy (<a id="xref-ref-40-1" class="xref-bibr" href="#ref-40">40</a>), might be explained by the inferior efficacy of carboplatin observed in our meta-analysis.
                  </p>
                  <p id="p-65">In conclusion, based on the results of the randomized trials conducted thus far, our individual patient data meta-analysis,
                     as well as the previous literature-based meta-analyses, cisplatin should remain the reference platinum agent for treatment
                     of NSCLC, at least in advanced disease patients with good prognosis and in those with earlier stage disease.
                  </p>
               </div>
               <div class="section fn-group" id="fn-group-1">
                  <div class="section-nav"><a href="#sec-20" title="Discussion" class="prev-section-link"><span>Previous Section</span></a><a href="#ref-list-1" title="References" class="next-section-link"><span>Next Section</span></a></div>
                  <h2>Footnotes</h2>
                  <ul>
                     <li class="fn" id="fn-13">
                        <p id="p-66">The granting agencies played no role in the design of the study, the collection of the data, the analysis and interpretation
                           of the data, the decision to submit the manuscript for publication, or the writing of the manuscript.
                        </p>
                     </li>
                  </ul>
               </div>
               <ul>
                  <li class="fn" id="copyright-statement-1">© The Author 2007. Published by Oxford University Press.</li>
               </ul>
               <div class="section ref-list" id="ref-list-1">
                  <div class="section-nav"><a href="#fn-group-1" title="Footnotes" class="prev-section-link"><span>Previous Section</span></a><div class="nav-placeholder"> </div>
                  </div>
                  <h2>References</h2>
                  <ol class="cit-list ref-use-labels">
                     <li><span class="ref-label">(1)</span><a class="rev-xref-ref" href="#xref-ref-1-1" title="View reference (1) in text"
                           id="ref-1">↵</a><div class="cit ref-cit ref-journal" id="cit-99.11.847.1"
                             data-doi="10.3322/canjclin.55.1.10">
                           <div class="cit-metadata">
                              <ol class="cit-auth-list">
                                 <li><span class="cit-auth"><span class="cit-name-surname">Jemal</span>  <span class="cit-name-given-names">A</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Murray</span>  <span class="cit-name-given-names">T</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Ward</span>  <span class="cit-name-given-names">E</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Samuels</span>  <span class="cit-name-given-names">A</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Tiwari</span>  <span class="cit-name-given-names">R</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Ghafoor</span>  <span class="cit-name-given-names">A</span></span>, 
                                 </li>
                                 <li><span class="cit-etal">et al</span></li>
                              </ol><cite>. <span class="cit-article-title">Cancer statistics, 2005</span>. <abbr class="cit-jnl-abbrev">CA Cancer J Clin</abbr> <span class="cit-pub-date">2005</span>;<span class="cit-vol">55</span>:<span class="cit-fpage">10</span>-<span class="cit-lpage">30</span>.</cite></div>
                           <div class="cit-extra"><a href="/external-ref?access_num=10.3322/canjclin.55.1.10&amp;link_type=DOI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">CrossRef</a><a href="/external-ref?access_num=15661684&amp;link_type=MED"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-medline">Medline</a><a href="/external-ref?access_num=000231483900007&amp;link_type=ISI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">Web of Science</a><a target="_blank"
                                 href="http://scholar.google.com/scholar_lookup?title=Cancer%20statistics%2C%202005&amp;author=A%20Jemal&amp;author=T%20Murray&amp;author=E%20Ward&amp;author=A%20Samuels&amp;author=R%20Tiwari&amp;author=A%20Ghafoor&amp;publication_year=2005&amp;journal=CA%20Cancer%20J%20Clin&amp;volume=55&amp;pages=10-30">Google Scholar</a></div>
                        </div>
                     </li>
                     <li><span class="ref-label">(2)</span><a class="rev-xref-ref" href="#xref-ref-2-1" title="View reference (2) in text"
                           id="ref-2">↵</a><div class="cit ref-cit ref-journal" id="cit-99.11.847.2"
                             data-doi="10.1136/bmj.311.7010.899">
                           <div class="cit-metadata"><cite><span class="cit-auth cit-collab">Non-Small Cell Lung Cancer Collaborative Group</span>. <span class="cit-article-title">Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical
                                    trials</span>. <abbr class="cit-jnl-abbrev">BMJ</abbr> <span class="cit-pub-date">1995</span>;<span class="cit-vol">311</span>:<span class="cit-fpage">899</span>-<span class="cit-lpage">909</span>.</cite></div>
                           <div class="cit-extra"><a href="/cgi/ijlink?linkType=ABST&amp;journalCode=bmj&amp;resid=311/7010/899"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-ijlinks"><span class="cit-reflinks-abstract">Abstract</span><span class="cit-sep cit-reflinks-variant-name-sep">/</span><span class="cit-reflinks-full-text"><span class="free-full-text">FREE </span>Full Text</span></a></div>
                        </div>
                     </li>
                     <li><span class="ref-label">(3)</span><a class="rev-xref-ref" href="#xref-ref-3-1" title="View reference (3) in text"
                           id="ref-3">↵</a><div class="cit ref-cit ref-journal" id="cit-99.11.847.3">
                           <div class="cit-metadata">
                              <ol class="cit-auth-list">
                                 <li><span class="cit-auth"><span class="cit-name-surname">Cullen</span>  <span class="cit-name-given-names">MH</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Billingham</span>  <span class="cit-name-given-names">LJ</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Woodroffe</span>  <span class="cit-name-given-names">CM</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Chetiyawardana</span>  <span class="cit-name-given-names">AD</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Gower</span>  <span class="cit-name-given-names">NH</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Joshi</span>  <span class="cit-name-given-names">R</span></span>, 
                                 </li>
                                 <li><span class="cit-etal">et al</span></li>
                              </ol><cite>. <span class="cit-article-title">Mitomycin, ifosfamide, and cisplatin in unresectable non-small-cell lung cancer: effects on survival and quality of life</span>. <abbr class="cit-jnl-abbrev">J Clin Oncol</abbr> <span class="cit-pub-date">1999</span>;<span class="cit-vol">17</span>:<span class="cit-fpage">3188</span>-<span class="cit-lpage">94</span>.</cite></div>
                           <div class="cit-extra"><a href="/cgi/ijlink?linkType=ABST&amp;journalCode=jco&amp;resid=17/10/3188"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-ijlinks"><span class="cit-reflinks-abstract">Abstract</span><span class="cit-sep cit-reflinks-variant-name-sep">/</span><span class="cit-reflinks-full-text"><span class="free-full-text">FREE </span>Full Text</span></a></div>
                        </div>
                     </li>
                     <li><span class="ref-label">(4)</span><a class="rev-xref-ref" href="#xref-ref-4-1" title="View reference (4) in text"
                           id="ref-4">↵</a><div class="cit ref-cit ref-journal" id="cit-99.11.847.4"
                             data-doi="10.1038/sj.bjc.6600491">
                           <div class="cit-metadata">
                              <ol class="cit-auth-list">
                                 <li><span class="cit-auth"><span class="cit-name-surname">Waters</span>  <span class="cit-name-given-names">JS</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">O’Brien</span>  <span class="cit-name-given-names">MER</span></span></li>
                              </ol><cite>. <span class="cit-article-title">The case for the introduction of new chemotherapy agents in the treatment of advanced non-small cell lung cancer in the wake
                                    of the findings of The National Institute of Clinical Excellence (NICE)</span>. <abbr class="cit-jnl-abbrev">Br J Cancer</abbr> <span class="cit-pub-date">2002</span>;<span class="cit-vol">87</span>:<span class="cit-fpage">481</span>-<span class="cit-lpage">90</span>.</cite></div>
                           <div class="cit-extra"><a href="/external-ref?access_num=10.1038/sj.bjc.6600491&amp;link_type=DOI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">CrossRef</a><a href="/external-ref?access_num=12189541&amp;link_type=MED"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-medline">Medline</a><a href="/external-ref?access_num=000177985400002&amp;link_type=ISI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">Web of Science</a><a target="_blank"
                                 href="http://scholar.google.com/scholar_lookup?title=The%20case%20for%20the%20introduction%20of%20new%20chemotherapy%20agents%20in%20the%20treatment%20of%20advanced%20non-small%20cell%20lung%20cancer%20in%20the%20wake%20of%20the%20findings%20of%20The%20National%20Institute%20of%20Clinical%20Excellence%20%28NICE%29&amp;author=JS%20Waters&amp;author=MER%20O%E2%80%99Brien&amp;publication_year=2002&amp;journal=Br%20J%20Cancer&amp;volume=87&amp;pages=481-90">Google Scholar</a></div>
                        </div>
                     </li>
                     <li><span class="ref-label">(5)</span><a class="rev-xref-ref" href="#xref-ref-5-1" title="View reference (5) in text"
                           id="ref-5">↵</a><div class="cit ref-cit ref-book" id="cit-99.11.847.5"
                             data-doi="10.1200/JCO.2004.09.053">
                           <div class="cit-metadata">
                              <ol class="cit-auth-list">
                                 <li><span class="cit-auth"><span class="cit-name-surname">Pfister</span>  <span class="cit-name-given-names">DG</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Johnson</span>  <span class="cit-name-given-names">DH</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Azzoli</span>  <span class="cit-name-given-names">CG</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Sause</span>  <span class="cit-name-given-names">W</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Smith</span>  <span class="cit-name-given-names">TJ</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Baker</span>  <span class="cit-name-given-names">S</span>  <span class="cit-name-suffix">Jr</span></span>, 
                                 </li>
                                 <li><span class="cit-etal">et al</span></li>
                              </ol><cite>. <span class="cit-source">J Clin Oncol</span>. Vol. <span class="cit-vol">22</span>. <span class="cit-pub-date">2004</span>. <span class="cit-article-title">American Society of Clinical Oncology treatment of unresectable non-small-cell lung cancer guideline: update 2003</span>; p. <span class="cit-fpage">330</span>-<span class="cit-lpage">53</span>.</cite></div>
                           <div class="cit-extra"><a href="/cgi/ijlink?linkType=FULL&amp;journalCode=jco&amp;resid=22/2/330"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-ijlinks"><span class="cit-reflinks-full-text"><span class="free-full-text">FREE </span>Full Text</span></a></div>
                        </div>
                     </li>
                     <li><span class="ref-label">(6)</span><a class="rev-xref-ref" href="#xref-ref-6-1" title="View reference (6) in text"
                           id="ref-6">↵</a><div class="cit ref-cit ref-journal" id="cit-99.11.847.6">
                           <div class="cit-metadata">
                              <ol class="cit-auth-list">
                                 <li><span class="cit-auth"><span class="cit-name-surname">Evans</span>  <span class="cit-name-given-names">WK</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Newman</span>  <span class="cit-name-given-names">T</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Graham</span>  <span class="cit-name-given-names">I</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Rusthoven</span>  <span class="cit-name-given-names">JJ</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Logan</span>  <span class="cit-name-given-names">D</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Shepherd</span>  <span class="cit-name-given-names">FA</span></span>, 
                                 </li>
                                 <li><span class="cit-etal">et al</span></li>
                              </ol><cite>. <span class="cit-article-title">Lung cancer practice guidelines: lessons learned and issues addressed by the Ontario Lung Cancer Disease Site Group</span>. <abbr class="cit-jnl-abbrev">J Clin Oncol</abbr> <span class="cit-pub-date">1997</span>;<span class="cit-vol">15</span>:<span class="cit-fpage">3049</span>-<span class="cit-lpage">59</span>.</cite></div>
                           <div class="cit-extra"><a href="/cgi/ijlink?linkType=ABST&amp;journalCode=jco&amp;resid=15/9/3049"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-ijlinks"><span class="cit-reflinks-abstract">Abstract</span></a></div>
                        </div>
                     </li>
                     <li><span class="ref-label">(7)</span><a class="rev-xref-ref" href="#xref-ref-7-1" title="View reference (7) in text"
                           id="ref-7">↵</a><div class="cit ref-cit ref-journal" id="cit-99.11.847.7"
                             data-doi="10.1093/annonc/mdi821">
                           <div class="cit-metadata">
                              <ol class="cit-auth-list">
                                 <li><span class="cit-auth"><span class="cit-name-surname">Felip</span>  <span class="cit-name-given-names">E</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Stahel</span>  <span class="cit-name-given-names">RA</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Pavlidis</span>  <span class="cit-name-given-names">N</span></span></li>
                              </ol><cite>. <span class="cit-article-title">ESMO minimum clinical recommendations for diagnosis, treatment and follow-up of non-small-cell lung cancer (NSCLC)</span>. <abbr class="cit-jnl-abbrev">Ann Oncol</abbr> <span class="cit-pub-date">2005</span>;<span class="cit-vol">16</span>:<span class="cit-fpage">i28</span>-<span class="cit-lpage">9</span>.</cite></div>
                           <div class="cit-extra"><a href="/cgi/ijlink?linkType=PDF&amp;journalCode=annonc&amp;resid=16/suppl_1/i28"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-ijlinks"><span class="cit-reflinks-full-text"><span class="free-full-text">FREE </span>Full Text</span></a></div>
                        </div>
                     </li>
                     <li><span class="ref-label">(8)</span><a class="rev-xref-ref" href="#xref-ref-8-1" title="View reference (8) in text"
                           id="ref-8">↵</a><div class="cit ref-cit ref-book" id="cit-99.11.847.8">
                           <div class="cit-metadata">
                              <ol class="cit-ed-list duplicate">
                                 <li><span class="cit-ed"><span class="cit-name-surname">De Vita</span>  <span class="cit-name-given-names">VT</span>  <span class="cit-name-suffix">Jr</span></span>, 
                                 </li>
                                 <li><span class="cit-ed"><span class="cit-name-surname">Hellman</span>  <span class="cit-name-given-names">S</span></span>, 
                                 </li>
                                 <li><span class="cit-ed"><span class="cit-name-surname">Rosenberg</span>  <span class="cit-name-given-names">SA</span></span></li>
                              </ol>
                              <ol class="cit-auth-list">
                                 <li><span class="cit-auth"><span class="cit-name-surname">Johnson</span>  <span class="cit-name-given-names">SW</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">O’Dwyer</span>  <span class="cit-name-given-names">PJ</span></span></li>
                              </ol><cite>. <span class="cit-article-title">Pharmacology of cancer chemotherapy: cisplatin and its analogues</span>. In: <span class="cit-ed"><span class="cit-name-surname">De Vita</span>  <span class="cit-name-given-names">VT</span>  <span class="cit-name-suffix">Jr</span></span>, <span class="cit-ed"><span class="cit-name-surname">Hellman</span>  <span class="cit-name-given-names">S</span></span>, <span class="cit-ed"><span class="cit-name-surname">Rosenberg</span>  <span class="cit-name-given-names">SA</span></span>, editors. <span class="cit-source">Cancer: principles and practice of oncology</span>. <span class="cit-edition">7th ed</span>. <span class="cit-publ-loc">Philadelphia (PA)</span>: <span class="cit-publ-name">Lippincott Williams &amp; Wilkins</span>; <span class="cit-pub-date">2005</span>. p. <span class="cit-fpage">344</span>-<span class="cit-lpage">58</span>.</cite></div>
                           <div class="cit-extra"><a target="_blank"
                                 href="http://scholar.google.com/scholar_lookup?title=Pharmacology%20of%20cancer%20chemotherapy%3A%20cisplatin%20and%20its%20analogues&amp;author=SW%20Johnson&amp;author=PJ%20O%E2%80%99Dwyer&amp;publication_year=2005&amp;citation_inbook_title=Cancer%3A%20principles%20and%20practice%20of%20oncology">Google Scholar</a></div>
                        </div>
                     </li>
                     <li><span class="ref-label">(9)</span><a class="rev-xref-ref" href="#xref-ref-9-1" title="View reference (9) in text"
                           id="ref-9">↵</a><div class="cit ref-cit ref-journal" id="cit-99.11.847.9">
                           <div class="cit-metadata">
                              <ol class="cit-auth-list">
                                 <li><span class="cit-auth"><span class="cit-name-surname">Go</span>  <span class="cit-name-given-names">RS</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Adjei</span>  <span class="cit-name-given-names">AA</span></span></li>
                              </ol><cite>. <span class="cit-article-title">Review of the comparative pharmacology and clinical activity of cisplatin and carboplatin</span>. <abbr class="cit-jnl-abbrev">J Clin Oncol</abbr> <span class="cit-pub-date">1999</span>;<span class="cit-vol">17</span>:<span class="cit-fpage">409</span>-<span class="cit-lpage">22</span>.</cite></div>
                           <div class="cit-extra"><a href="/cgi/ijlink?linkType=ABST&amp;journalCode=jco&amp;resid=17/1/409"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-ijlinks"><span class="cit-reflinks-abstract">Abstract</span><span class="cit-sep cit-reflinks-variant-name-sep">/</span><span class="cit-reflinks-full-text"><span class="free-full-text">FREE </span>Full Text</span></a></div>
                        </div>
                     </li>
                     <li><span class="ref-label">(10)</span><a class="rev-xref-ref" href="#xref-ref-10-1" title="View reference (10) in text"
                           id="ref-10">↵</a><div class="cit ref-cit ref-journal" id="cit-99.11.847.10"
                             data-doi="10.1023/A:1008215213739">
                           <div class="cit-metadata">
                              <ol class="cit-auth-list">
                                 <li><span class="cit-auth"><span class="cit-name-surname">Lokich</span>  <span class="cit-name-given-names">J</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Anderson</span>  <span class="cit-name-given-names">N</span></span></li>
                              </ol><cite>. <span class="cit-article-title">Carboplatin versus cisplatin in solid tumors: an analysis of the literature</span>. <abbr class="cit-jnl-abbrev">Ann Oncol</abbr> <span class="cit-pub-date">1998</span>;<span class="cit-vol">9</span>:<span class="cit-fpage">13</span>-<span class="cit-lpage">21</span>.</cite></div>
                           <div class="cit-extra"><a href="/cgi/ijlink?linkType=ABST&amp;journalCode=annonc&amp;resid=9/1/13"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-ijlinks"><span class="cit-reflinks-abstract">Abstract</span><span class="cit-sep cit-reflinks-variant-name-sep">/</span><span class="cit-reflinks-full-text"><span class="free-full-text">FREE </span>Full Text</span></a></div>
                        </div>
                     </li>
                     <li><span class="ref-label">(11)</span><a class="rev-xref-ref" href="#xref-ref-11-1" title="View reference (11) in text"
                           id="ref-11">↵</a><div class="cit ref-cit ref-journal" id="cit-99.11.847.11">
                           <div class="cit-metadata">
                              <ol class="cit-auth-list">
                                 <li><span class="cit-auth"><span class="cit-name-surname">Berghmans</span>  <span class="cit-name-given-names">T</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Paesmans</span>  <span class="cit-name-given-names">M</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Sculier</span>  <span class="cit-name-given-names">JP</span></span></li>
                              </ol><cite>. <span class="cit-article-title">Cisplatin or carboplatin for the treatment of non-small cell lung cancer: do they have equivalent efficacy?</span> <abbr class="cit-jnl-abbrev">Lung Cancer</abbr> <span class="cit-pub-date">2001</span>;<span class="cit-vol">34</span>:<span class="cit-fpage">15</span>-<span class="cit-lpage">7</span>.</cite></div>
                           <div class="cit-extra"><a href="/external-ref?access_num=11557108&amp;link_type=MED"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-medline">Medline</a><a href="/external-ref?access_num=000171684300002&amp;link_type=ISI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">Web of Science</a><a target="_blank"
                                 href="http://scholar.google.com/scholar_lookup?title=Cisplatin%20or%20carboplatin%20for%20the%20treatment%20of%20non-small%20cell%20lung%20cancer%3A%20do%20they%20have%20equivalent%20efficacy%3F&amp;author=T%20Berghmans&amp;author=M%20Paesmans&amp;author=JP%20Sculier&amp;publication_year=2001&amp;journal=Lung%20Cancer&amp;volume=34&amp;pages=15-7">Google Scholar</a></div>
                        </div>
                     </li>
                     <li><span class="ref-label">(12)</span><div class="cit ref-cit ref-journal no-rev-xref" id="cit-99.11.847.12"
                             data-doi="10.1093/annonc/mdf331">
                           <div class="cit-metadata">
                              <ol class="cit-auth-list">
                                 <li><span class="cit-auth"><span class="cit-name-surname">Soria</span>  <span class="cit-name-given-names">JC</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Le Chevalier</span>  <span class="cit-name-given-names">T</span></span></li>
                              </ol><cite>. <span class="cit-article-title">Is cisplatin still the best platinum compound in non-small-cell lung cancer?</span> <abbr class="cit-jnl-abbrev">Ann Oncol</abbr> <span class="cit-pub-date">2002</span>;<span class="cit-vol">13</span>:<span class="cit-fpage">1515</span>-<span class="cit-lpage">7</span>.</cite></div>
                           <div class="cit-extra"><a href="/cgi/ijlink?linkType=FULL&amp;journalCode=annonc&amp;resid=13/10/1515"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-ijlinks"><span class="cit-reflinks-full-text"><span class="free-full-text">FREE </span>Full Text</span></a></div>
                        </div>
                     </li>
                     <li><span class="ref-label">(13)</span><a class="rev-xref-ref" href="#xref-ref-13-1" title="View reference (13) in text"
                           id="ref-13">↵</a><div class="cit ref-cit ref-journal" id="cit-99.11.847.13">
                           <div class="cit-metadata">
                              <ol class="cit-auth-list">
                                 <li><span class="cit-auth"><span class="cit-name-surname">Einhorn</span>  <span class="cit-name-given-names">LH</span></span></li>
                              </ol><cite>. <span class="cit-article-title">Carboplatin versus cisplatin in lung cancer</span>. <abbr class="cit-jnl-abbrev">Lung Cancer</abbr> <span class="cit-pub-date">2005</span>;<span class="cit-vol">49</span> <span class="cit-supplement">Suppl 3</span>:<span class="cit-fpage">S32</span>-<span class="cit-lpage">5</span>.</cite></div>
                           <div class="cit-extra"><a target="_blank"
                                 href="http://scholar.google.com/scholar_lookup?title=Carboplatin%20versus%20cisplatin%20in%20lung%20cancer&amp;author=LH%20Einhorn&amp;publication_year=2005&amp;journal=Lung%20Cancer&amp;volume=49&amp;pages=S32-5">Google Scholar</a></div>
                        </div>
                     </li>
                     <li><span class="ref-label">(14)</span><a class="rev-xref-ref" href="#xref-ref-14-1" title="View reference (14) in text"
                           id="ref-14">↵</a><div class="cit ref-cit ref-book" id="cit-99.11.847.14">
                           <div class="cit-metadata">
                              <ol class="cit-auth-list">
                                 <li><span class="cit-auth"><span class="cit-name-surname">Kelly</span>  <span class="cit-name-given-names">K</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Crowley</span>  <span class="cit-name-given-names">J</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Bunn</span>  <span class="cit-name-given-names">PA</span>  <span class="cit-name-suffix">Jr</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Presant</span>  <span class="cit-name-given-names">CA</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Grevstad</span>  <span class="cit-name-given-names">PK</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Moinpour</span>  <span class="cit-name-given-names">CM</span></span>, 
                                 </li>
                                 <li><span class="cit-etal">et al</span></li>
                              </ol><cite>. <span class="cit-source">J Clin Oncol</span>. Vol. <span class="cit-vol">19</span>. <span class="cit-pub-date">2001</span>. <span class="cit-article-title">Randomized phase III trial of paclitaxel plus carboplatin versus vinorelbine plus cisplatin in the treatment of patients with
                                    advanced non-small-cell lung cancer: a Southwest Oncology Group trial</span>; p. <span class="cit-fpage">3210</span>-<span class="cit-lpage">8</span>.</cite></div>
                           <div class="cit-extra"><a href="/cgi/ijlink?linkType=ABST&amp;journalCode=jco&amp;resid=19/13/3210"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-ijlinks"><span class="cit-reflinks-abstract">Abstract</span><span class="cit-sep cit-reflinks-variant-name-sep">/</span><span class="cit-reflinks-full-text"><span class="free-full-text">FREE </span>Full Text</span></a></div>
                        </div>
                     </li>
                     <li><span class="ref-label">(15)</span><a class="rev-xref-ref" href="#xref-ref-15-1" title="View reference (15) in text"
                           id="ref-15">↵</a><div class="cit ref-cit ref-journal" id="cit-99.11.847.15"
                             data-doi="10.1200/JCO.2002.02.068">
                           <div class="cit-metadata">
                              <ol class="cit-auth-list">
                                 <li><span class="cit-auth"><span class="cit-name-surname">Scagliotti</span>  <span class="cit-name-given-names">GV</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">De Marinis</span>  <span class="cit-name-given-names">F</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Rinaldi</span>  <span class="cit-name-given-names">M</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Crinò</span>  <span class="cit-name-given-names">L</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Gridelli</span>  <span class="cit-name-given-names">C</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Ricci</span>  <span class="cit-name-given-names">S</span></span>, 
                                 </li>
                                 <li><span class="cit-etal">et al</span></li>
                              </ol><cite>. <span class="cit-article-title">Phase III randomized trial comparing three platinum based doublets in advanced non small cell lung cancer</span>. <abbr class="cit-jnl-abbrev">J Clin Oncol</abbr> <span class="cit-pub-date">2002</span>;<span class="cit-vol">20</span>:<span class="cit-fpage">4285</span>-<span class="cit-lpage">91</span>.</cite></div>
                           <div class="cit-extra"><a href="/cgi/ijlink?linkType=ABST&amp;journalCode=jco&amp;resid=20/21/4285"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-ijlinks"><span class="cit-reflinks-abstract">Abstract</span><span class="cit-sep cit-reflinks-variant-name-sep">/</span><span class="cit-reflinks-full-text"><span class="free-full-text">FREE </span>Full Text</span></a></div>
                        </div>
                     </li>
                     <li><span class="ref-label">(16)</span><a class="rev-xref-ref" href="#xref-ref-16-1" title="View reference (16) in text"
                           id="ref-16">↵</a><div class="cit ref-cit ref-journal" id="cit-99.11.847.16"
                             data-doi="10.1016/S0033-0620(85)80003-7">
                           <div class="cit-metadata">
                              <ol class="cit-auth-list">
                                 <li><span class="cit-auth"><span class="cit-name-surname">Yusuf</span>  <span class="cit-name-given-names">S</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Peto</span>  <span class="cit-name-given-names">R</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Lewis</span>  <span class="cit-name-given-names">J</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Collins</span>  <span class="cit-name-given-names">R</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Sleight</span>  <span class="cit-name-given-names">T</span></span></li>
                              </ol><cite>. <span class="cit-article-title">Beta blockade during and after myocardial infarction: an overview of the randomised trials</span>. <abbr class="cit-jnl-abbrev">Prog Cardiovasc Dis</abbr> <span class="cit-pub-date">1985</span>;<span class="cit-vol">27</span>:<span class="cit-fpage">335</span>-<span class="cit-lpage">71</span>.</cite></div>
                           <div class="cit-extra"><a href="/external-ref?access_num=10.1016/S0033-0620(85)80003-7&amp;link_type=DOI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">CrossRef</a><a href="/external-ref?access_num=2858114&amp;link_type=MED"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-medline">Medline</a><a href="/external-ref?access_num=A1985AEJ1700003&amp;link_type=ISI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">Web of Science</a><a target="_blank"
                                 href="http://scholar.google.com/scholar_lookup?title=Beta%20blockade%20during%20and%20after%20myocardial%20infarction%3A%20an%20overview%20of%20the%20randomised%20trials&amp;author=S%20Yusuf&amp;author=R%20Peto&amp;author=J%20Lewis&amp;author=R%20Collins&amp;author=T%20Sleight&amp;publication_year=1985&amp;journal=Prog%20Cardiovasc%20Dis&amp;volume=27&amp;pages=335-71">Google Scholar</a></div>
                        </div>
                     </li>
                     <li><span class="ref-label">(17)</span><a class="rev-xref-ref" href="#xref-ref-17-1" title="View reference (17) in text"
                           id="ref-17">↵</a><div class="cit ref-cit ref-journal" id="cit-99.11.847.17"
                             data-doi="10.1002/sim.4780101105">
                           <div class="cit-metadata">
                              <ol class="cit-auth-list">
                                 <li><span class="cit-auth"><span class="cit-name-surname">Whitehead</span>  <span class="cit-name-given-names">A</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Whitehead</span>  <span class="cit-name-given-names">J</span></span></li>
                              </ol><cite>. <span class="cit-article-title">A general parametric approach to the meta-analysis of randomized clinical trials</span>. <abbr class="cit-jnl-abbrev">Stat Med</abbr> <span class="cit-pub-date">1991</span>;<span class="cit-vol">10</span>:<span class="cit-fpage">1665</span>-<span class="cit-lpage">77</span>.</cite></div>
                           <div class="cit-extra"><a href="/external-ref?access_num=10.1002/sim.4780101105&amp;link_type=DOI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">CrossRef</a><a href="/external-ref?access_num=1792461&amp;link_type=MED"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-medline">Medline</a><a href="/external-ref?access_num=A1991GU26700003&amp;link_type=ISI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">Web of Science</a><a target="_blank"
                                 href="http://scholar.google.com/scholar_lookup?title=A%20general%20parametric%20approach%20to%20the%20meta-analysis%20of%20randomized%20clinical%20trials&amp;author=A%20Whitehead&amp;author=J%20Whitehead&amp;publication_year=1991&amp;journal=Stat%20Med&amp;volume=10&amp;pages=1665-77">Google Scholar</a></div>
                        </div>
                     </li>
                     <li><span class="ref-label">(18)</span><a class="rev-xref-ref" href="#xref-ref-18-1" title="View reference (18) in text"
                           id="ref-18">↵</a><div class="cit ref-cit ref-journal" id="cit-99.11.847.18">
                           <div class="cit-metadata">
                              <ol class="cit-auth-list">
                                 <li><span class="cit-auth"><span class="cit-name-surname">Cochran</span>  <span class="cit-name-given-names">WG</span></span></li>
                              </ol><cite>. <span class="cit-article-title">The combination of estimates from different experiments</span>. <abbr class="cit-jnl-abbrev">Biometrics</abbr> <span class="cit-pub-date">1954</span>;<span class="cit-vol">10</span>:<span class="cit-fpage">101</span>-<span class="cit-lpage">29</span>.</cite></div>
                           <div class="cit-extra"><a href="/external-ref?access_num=13197148&amp;link_type=MED"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-medline">Medline</a><a target="_blank"
                                 href="http://scholar.google.com/scholar_lookup?title=The%20combination%20of%20estimates%20from%20different%20experiments&amp;author=WG%20Cochran&amp;publication_year=1954&amp;journal=Biometrics&amp;volume=10&amp;pages=101-29">Google Scholar</a></div>
                        </div>
                     </li>
                     <li><span class="ref-label">(19)</span><a class="rev-xref-ref" href="#xref-ref-19-1" title="View reference (19) in text"
                           id="ref-19">↵</a><div class="cit ref-cit ref-journal" id="cit-99.11.847.19"
                             data-doi="10.1002/sim.1186">
                           <div class="cit-metadata">
                              <ol class="cit-auth-list">
                                 <li><span class="cit-auth"><span class="cit-name-surname">Higgins</span>  <span class="cit-name-given-names">JPT</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Thompson</span>  <span class="cit-name-given-names">SG</span></span></li>
                              </ol><cite>. <span class="cit-article-title">Quantifying heterogeneity in a meta-analysis</span>. <abbr class="cit-jnl-abbrev">Stat Med</abbr> <span class="cit-pub-date">2002</span>;<span class="cit-vol">21</span>:<span class="cit-fpage">1539</span>-<span class="cit-lpage">58</span>.</cite></div>
                           <div class="cit-extra"><a href="/external-ref?access_num=10.1002/sim.1186&amp;link_type=DOI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">CrossRef</a><a href="/external-ref?access_num=12111919&amp;link_type=MED"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-medline">Medline</a><a href="/external-ref?access_num=000176016900005&amp;link_type=ISI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">Web of Science</a><a target="_blank"
                                 href="http://scholar.google.com/scholar_lookup?title=Quantifying%20heterogeneity%20in%20a%20meta-analysis&amp;author=JPT%20Higgins&amp;author=SG%20Thompson&amp;publication_year=2002&amp;journal=Stat%20Med&amp;volume=21&amp;pages=1539-58">Google Scholar</a></div>
                        </div>
                     </li>
                     <li><span class="ref-label">(20)</span><a class="rev-xref-ref" href="#xref-ref-20-1" title="View reference (20) in text"
                           id="ref-20">↵</a><div class="cit ref-cit ref-journal" id="cit-99.11.847.20"
                             data-doi="10.1016/j.jclinepi.2004.08.013">
                           <div class="cit-metadata">
                              <ol class="cit-auth-list">
                                 <li><span class="cit-auth"><span class="cit-name-surname">Michiels</span>  <span class="cit-name-given-names">S</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Baujat</span>  <span class="cit-name-given-names">B</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Mahè</span>  <span class="cit-name-given-names">C</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Sargent</span>  <span class="cit-name-given-names">DJ</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Pignon</span>  <span class="cit-name-given-names">JP</span></span></li>
                              </ol><cite>. <span class="cit-article-title">Random effects survival models gave a better understanding of heterogeneity in individual patient data meta-analyses</span>. <abbr class="cit-jnl-abbrev">J Clin Epidemiol</abbr> <span class="cit-pub-date">2005</span>;<span class="cit-vol">58</span>:<span class="cit-fpage">238</span>-<span class="cit-lpage">45</span>.</cite></div>
                           <div class="cit-extra"><a href="/external-ref?access_num=10.1016/j.jclinepi.2004.08.013&amp;link_type=DOI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">CrossRef</a><a href="/external-ref?access_num=15718112&amp;link_type=MED"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-medline">Medline</a><a href="/external-ref?access_num=000227510500005&amp;link_type=ISI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">Web of Science</a><a target="_blank"
                                 href="http://scholar.google.com/scholar_lookup?title=Random%20effects%20survival%20models%20gave%20a%20better%20understanding%20of%20heterogeneity%20in%20individual%20patient%20data%20meta-analyses&amp;author=S%20Michiels&amp;author=B%20Baujat&amp;author=C%20Mah%C3%A8&amp;author=DJ%20Sargent&amp;author=JP%20Pignon&amp;publication_year=2005&amp;journal=J%20Clin%20Epidemiol&amp;volume=58&amp;pages=238-45">Google Scholar</a></div>
                        </div>
                     </li>
                     <li><span class="ref-label">(21)</span><a class="rev-xref-ref" href="#xref-ref-21-1" title="View reference (21) in text"
                           id="ref-21">↵</a><div class="cit ref-cit ref-journal" id="cit-99.11.847.21"
                             data-doi="10.1016/0197-2456(96)00075-X">
                           <div class="cit-metadata">
                              <ol class="cit-auth-list">
                                 <li><span class="cit-auth"><span class="cit-name-surname">Schemper</span>  <span class="cit-name-given-names">M</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Smith</span>  <span class="cit-name-given-names">TL</span></span></li>
                              </ol><cite>. <span class="cit-article-title">A note on quantifying follow-up in studies of failure time</span>. <abbr class="cit-jnl-abbrev">Control Clin Trials</abbr> <span class="cit-pub-date">1996</span>;<span class="cit-vol">17</span>:<span class="cit-fpage">343</span>-<span class="cit-lpage">6</span>.</cite></div>
                           <div class="cit-extra"><a href="/external-ref?access_num=10.1016/0197-2456(96)00075-X&amp;link_type=DOI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">CrossRef</a><a href="/external-ref?access_num=8889347&amp;link_type=MED"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-medline">Medline</a><a href="/external-ref?access_num=A1996VK40600008&amp;link_type=ISI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">Web of Science</a><a target="_blank"
                                 href="http://scholar.google.com/scholar_lookup?title=A%20note%20on%20quantifying%20follow-up%20in%20studies%20of%20failure%20time&amp;author=M%20Schemper&amp;author=TL%20Smith&amp;publication_year=1996&amp;journal=Control%20Clin%20Trials&amp;volume=17&amp;pages=343-6">Google Scholar</a></div>
                        </div>
                     </li>
                     <li><span class="ref-label">(22)</span><a class="rev-xref-ref" href="#xref-ref-22-1" title="View reference (22) in text"
                           id="ref-22">↵</a><div class="cit ref-cit ref-journal" id="cit-99.11.847.22"
                             data-doi="10.1200/JCO.2004.02.109">
                           <div class="cit-metadata">
                              <ol class="cit-auth-list">
                                 <li><span class="cit-auth"><span class="cit-name-surname">Hotta</span>  <span class="cit-name-given-names">K</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Matsuo</span>  <span class="cit-name-given-names">K</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Ueoka</span>  <span class="cit-name-given-names">H</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Kiura</span>  <span class="cit-name-given-names">K</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Tabata</span>  <span class="cit-name-given-names">M</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Tanimoto</span>  <span class="cit-name-given-names">M</span></span></li>
                              </ol><cite>. <span class="cit-article-title">Meta-analysis of randomized clinical trials comparing cisplatin to carboplatin in patients with advanced non-small-cell lung
                                    cancer</span>. <abbr class="cit-jnl-abbrev">J Clin Oncol</abbr> <span class="cit-pub-date">2004</span>;<span class="cit-vol">22</span>:<span class="cit-fpage">3852</span>-<span class="cit-lpage">9</span>.</cite></div>
                           <div class="cit-extra"><a href="/cgi/ijlink?linkType=ABST&amp;journalCode=jco&amp;resid=22/19/3852"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-ijlinks"><span class="cit-reflinks-abstract">Abstract</span><span class="cit-sep cit-reflinks-variant-name-sep">/</span><span class="cit-reflinks-full-text"><span class="free-full-text">FREE </span>Full Text</span></a></div>
                        </div>
                     </li>
                     <li><span class="ref-label">(23)</span><a class="rev-xref-ref" href="#xref-ref-23-1" title="View reference (23) in text"
                           id="ref-23">↵</a><div class="cit ref-cit ref-journal" id="cit-99.11.847.23">
                           <div class="cit-metadata">
                              <ol class="cit-auth-list">
                                 <li><span class="cit-auth"><span class="cit-name-surname">Zojwalla</span>  <span class="cit-name-given-names">NJ</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Raftopoulos</span>  <span class="cit-name-given-names">H</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Gralla</span>  <span class="cit-name-given-names">RJ</span></span></li>
                              </ol><cite>. <span class="cit-article-title">Are cisplatin and carboplatin equivalent in the treatment of non-small cell lung carcinoma (NSCLC)? Results of a comprehensive
                                    review of randomized studies in over 2500 patients</span>. <abbr class="cit-jnl-abbrev">Proc Am Soc Clin Oncol</abbr> <span class="cit-pub-date">2004</span>;<span class="cit-vol">23</span>:<span class="cit-fpage">630a</span>.</cite></div>
                           <div class="cit-extra"><a target="_blank"
                                 href="http://scholar.google.com/scholar_lookup?title=Are%20cisplatin%20and%20carboplatin%20equivalent%20in%20the%20treatment%20of%20non-small%20cell%20lung%20carcinoma%20%28NSCLC%29%3F%20Results%20of%20a%20comprehensive%20review%20of%20randomized%20studies%20in%20over%202500%20patients&amp;author=NJ%20Zojwalla&amp;author=H%20Raftopoulos&amp;author=RJ%20Gralla&amp;publication_year=2004&amp;journal=Proc%20Am%20Soc%20Clin%20Oncol&amp;volume=23&amp;pages=630a">Google Scholar</a></div>
                        </div>
                     </li>
                     <li><span class="ref-label">(24)</span><a class="rev-xref-ref" href="#xref-ref-24-1" title="View reference (24) in text"
                           id="ref-24">↵</a><div class="cit ref-cit ref-book" id="cit-99.11.847.24">
                           <div class="cit-metadata">
                              <ol class="cit-auth-list">
                                 <li><span class="cit-auth"><span class="cit-name-surname">Whitehead</span>  <span class="cit-name-given-names">A</span></span></li>
                              </ol><cite>. <span class="cit-source">Meta-analysis of controlled clinical trials</span>. <span class="cit-publ-loc">Chichester (U.K.)</span>: <span class="cit-publ-name">John Wiley &amp; Sons</span>; <span class="cit-pub-date">2002</span>.</cite></div>
                           <div class="cit-extra"><a target="_blank"
                                 href="http://scholar.google.com/scholar_lookup?title=Meta-analysis%20of%20controlled%20clinical%20trials&amp;author=A%20Whitehead&amp;publication_year=2002">Google Scholar</a></div>
                        </div>
                     </li>
                     <li><span class="ref-label">(25)</span><a class="rev-xref-ref" href="#xref-ref-25-1" title="View reference (25) in text"
                           id="ref-25">↵</a><div class="cit ref-cit ref-journal" id="cit-99.11.847.25">
                           <div class="cit-metadata">
                              <ol class="cit-auth-list">
                                 <li><span class="cit-auth"><span class="cit-name-surname">Klastersky</span>  <span class="cit-name-given-names">J</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Sculier</span>  <span class="cit-name-given-names">J</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Lacroix</span>  <span class="cit-name-given-names">J</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Dabouis</span>  <span class="cit-name-given-names">G</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Bureau</span>  <span class="cit-name-given-names">G</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Libert</span>  <span class="cit-name-given-names">P</span></span>, 
                                 </li>
                                 <li><span class="cit-etal">et al</span></li>
                              </ol><cite>. <span class="cit-article-title">A randomized study comparing cisplatin or carboplatin with etoposide in patients with advanced non-small cell lung cancer:
                                    European Organization for Research and Treatment of Cancer protocol 07861</span>. <abbr class="cit-jnl-abbrev">J Clin Oncol</abbr> <span class="cit-pub-date">1990</span>;<span class="cit-vol">8</span>:<span class="cit-fpage">1556</span>-<span class="cit-lpage">62</span>.</cite></div>
                           <div class="cit-extra"><a href="/cgi/ijlink?linkType=ABST&amp;journalCode=jco&amp;resid=8/9/1556"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-ijlinks"><span class="cit-reflinks-abstract">Abstract</span></a></div>
                        </div>
                     </li>
                     <li><span class="ref-label">(26)</span><a class="rev-xref-ref" href="#xref-ref-26-1" title="View reference (26) in text"
                           id="ref-26">↵</a><div class="cit ref-cit ref-journal" id="cit-99.11.847.26">
                           <div class="cit-metadata">
                              <ol class="cit-auth-list">
                                 <li><span class="cit-auth"><span class="cit-name-surname">Jelic</span>  <span class="cit-name-given-names">S</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Mitrovic</span>  <span class="cit-name-given-names">L</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Radosavljevic</span>  <span class="cit-name-given-names">D</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Elezar</span>  <span class="cit-name-given-names">E</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Babovic</span>  <span class="cit-name-given-names">N</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Kovcin</span>  <span class="cit-name-given-names">V</span></span>, 
                                 </li>
                                 <li><span class="cit-etal">et al</span></li>
                              </ol><cite>. <span class="cit-article-title">Survival advantage for carboplatin substituting cisplatin in combination with vindesine and mitomycin C for stage IIIB and
                                    IV squamous-cell bronchogenic carcinoma: a randomized phase III study</span>. <abbr class="cit-jnl-abbrev">Lung Cancer</abbr> <span class="cit-pub-date">2001</span>;<span class="cit-vol">34</span>:<span class="cit-fpage">1</span>-<span class="cit-lpage">13</span>.</cite></div>
                           <div class="cit-extra"><a href="/external-ref?access_num=11557107&amp;link_type=MED"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-medline">Medline</a><a href="/external-ref?access_num=000171684300001&amp;link_type=ISI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">Web of Science</a><a target="_blank"
                                 href="http://scholar.google.com/scholar_lookup?title=Survival%20advantage%20for%20carboplatin%20substituting%20cisplatin%20in%20combination%20with%20vindesine%20and%20mitomycin%20C%20for%20stage%20IIIB%20and%20IV%20squamous-cell%20bronchogenic%20carcinoma%3A%20a%20randomized%20phase%20III%20study&amp;author=S%20Jelic&amp;author=L%20Mitrovic&amp;author=D%20Radosavljevic&amp;author=E%20Elezar&amp;author=N%20Babovic&amp;author=V%20Kovcin&amp;publication_year=2001&amp;journal=Lung%20Cancer&amp;volume=34&amp;pages=1-13">Google Scholar</a></div>
                        </div>
                     </li>
                     <li><span class="ref-label">(27)</span><a class="rev-xref-ref" href="#xref-ref-27-1" title="View reference (27) in text"
                           id="ref-27">↵</a><div class="cit ref-cit ref-journal" id="cit-99.11.847.27">
                           <div class="cit-metadata">
                              <ol class="cit-auth-list">
                                 <li><span class="cit-auth"><span class="cit-name-surname">Bisset</span>  <span class="cit-name-given-names">D</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Nicolson</span>  <span class="cit-name-given-names">M</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Falk</span>  <span class="cit-name-given-names">S</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Dunlop</span>  <span class="cit-name-given-names">D</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Stares</span>  <span class="cit-name-given-names">N</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Loh</span>  <span class="cit-name-given-names">E</span></span></li>
                              </ol><cite>. <span class="cit-article-title">Randomized phase II study of tirapazamine with either cisplatin or carboplatin in advanced NSCLC</span>. <abbr class="cit-jnl-abbrev">Proc Am Soc Clin Oncol</abbr> <span class="cit-pub-date">2001</span>;<span class="cit-vol">20</span>:<span class="cit-fpage">346a</span>.</cite></div>
                           <div class="cit-extra"><a target="_blank"
                                 href="http://scholar.google.com/scholar_lookup?title=Randomized%20phase%20II%20study%20of%20tirapazamine%20with%20either%20cisplatin%20or%20carboplatin%20in%20advanced%20NSCLC&amp;author=D%20Bisset&amp;author=M%20Nicolson&amp;author=S%20Falk&amp;author=D%20Dunlop&amp;author=N%20Stares&amp;author=E%20Loh&amp;publication_year=2001&amp;journal=Proc%20Am%20Soc%20Clin%20Oncol&amp;volume=20&amp;pages=346a">Google Scholar</a></div>
                        </div>
                     </li>
                     <li><span class="ref-label">(28)</span><a class="rev-xref-ref" href="#xref-ref-28-1" title="View reference (28) in text"
                           id="ref-28">↵</a><div class="cit ref-cit ref-journal" id="cit-99.11.847.28"
                             data-doi="10.1093/annonc/mdf332">
                           <div class="cit-metadata">
                              <ol class="cit-auth-list">
                                 <li><span class="cit-auth"><span class="cit-name-surname">Rosell</span>  <span class="cit-name-given-names">R</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Gatzemeier</span>  <span class="cit-name-given-names">U</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Betticher</span>  <span class="cit-name-given-names">DC</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Keppler</span>  <span class="cit-name-given-names">U</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Macha</span>  <span class="cit-name-given-names">HN</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Pirker</span>  <span class="cit-name-given-names">R</span></span>, 
                                 </li>
                                 <li><span class="cit-etal">et al</span></li>
                              </ol><cite>. <span class="cit-article-title">Phase III randomised trial comparing paclitaxel/carboplatin with paclitaxel/cisplatin in patients with advanced non-small-cell
                                    lung cancer: a cooperative multinational trial</span>. <abbr class="cit-jnl-abbrev">Ann Oncol</abbr> <span class="cit-pub-date">2002</span>;<span class="cit-vol">13</span>:<span class="cit-fpage">1539</span>-<span class="cit-lpage">49</span>.</cite></div>
                           <div class="cit-extra"><a href="/cgi/ijlink?linkType=ABST&amp;journalCode=annonc&amp;resid=13/10/1539"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-ijlinks"><span class="cit-reflinks-abstract">Abstract</span><span class="cit-sep cit-reflinks-variant-name-sep">/</span><span class="cit-reflinks-full-text"><span class="free-full-text">FREE </span>Full Text</span></a></div>
                        </div>
                     </li>
                     <li><span class="ref-label">(29)</span><a class="rev-xref-ref" href="#xref-ref-29-1" title="View reference (29) in text"
                           id="ref-29">↵</a><div class="cit ref-cit ref-journal" id="cit-99.11.847.29"
                             data-doi="10.1056/NEJMoa011954">
                           <div class="cit-metadata">
                              <ol class="cit-auth-list">
                                 <li><span class="cit-auth"><span class="cit-name-surname">Schiller</span>  <span class="cit-name-given-names">JH</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Harrington</span>  <span class="cit-name-given-names">D</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Belani</span>  <span class="cit-name-given-names">CP</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Langer</span>  <span class="cit-name-given-names">C</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Sandler</span>  <span class="cit-name-given-names">A</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Krook</span>  <span class="cit-name-given-names">J</span></span>, 
                                 </li>
                                 <li><span class="cit-etal">et al</span></li>
                              </ol><cite>. <span class="cit-article-title">Comparison of four chemotherapy regimens for advanced non-small cell lung cancer</span>. <abbr class="cit-jnl-abbrev">N Engl J Med</abbr> <span class="cit-pub-date">2002</span>;<span class="cit-vol">346</span>:<span class="cit-fpage">92</span>-<span class="cit-lpage">8</span>.</cite></div>
                           <div class="cit-extra"><a href="/external-ref?access_num=10.1056/NEJMoa011954&amp;link_type=DOI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">CrossRef</a><a href="/external-ref?access_num=11784875&amp;link_type=MED"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-medline">Medline</a><a href="/external-ref?access_num=000173133400004&amp;link_type=ISI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">Web of Science</a><a target="_blank"
                                 href="http://scholar.google.com/scholar_lookup?title=Comparison%20of%20four%20chemotherapy%20regimens%20for%20advanced%20non-small%20cell%20lung%20cancer&amp;author=JH%20Schiller&amp;author=D%20Harrington&amp;author=CP%20Belani&amp;author=C%20Langer&amp;author=A%20Sandler&amp;author=J%20Krook&amp;publication_year=2002&amp;journal=N%20Engl%20J%20Med&amp;volume=346&amp;pages=92-8">Google Scholar</a></div>
                        </div>
                     </li>
                     <li><span class="ref-label">(30)</span><a class="rev-xref-ref" href="#xref-ref-30-1" title="View reference (30) in text"
                           id="ref-30">↵</a><div class="cit ref-cit ref-journal" id="cit-99.11.847.30"
                             data-doi="10.1016/S0169-5002(03)00233-2">
                           <div class="cit-metadata">
                              <ol class="cit-auth-list">
                                 <li><span class="cit-auth"><span class="cit-name-surname">Zatloukal</span>  <span class="cit-name-given-names">P</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Petruzelka</span>  <span class="cit-name-given-names">L</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Zemanova</span>  <span class="cit-name-given-names">M</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Kolek</span>  <span class="cit-name-given-names">V</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Skrickova</span>  <span class="cit-name-given-names">J</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Pesek</span>  <span class="cit-name-given-names">M</span></span>, 
                                 </li>
                                 <li><span class="cit-etal">et al</span></li>
                              </ol><cite>. <span class="cit-article-title">Gemcitabine plus cisplatin versus gemcitabine plus carboplatin in stage IIIB and IV non-small cell lung cancer (NSCLC): a
                                    phase III randomized trial</span>. <abbr class="cit-jnl-abbrev">Lung Cancer</abbr> <span class="cit-pub-date">2003</span>;<span class="cit-vol">41</span>:<span class="cit-fpage">321</span>-<span class="cit-lpage">31</span>.</cite></div>
                           <div class="cit-extra"><a href="/external-ref?access_num=10.1016/S0169-5002(03)00233-2&amp;link_type=DOI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">CrossRef</a><a href="/external-ref?access_num=12928123&amp;link_type=MED"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-medline">Medline</a><a href="/external-ref?access_num=000185347600008&amp;link_type=ISI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">Web of Science</a><a target="_blank"
                                 href="http://scholar.google.com/scholar_lookup?title=Gemcitabine%20plus%20cisplatin%20versus%20gemcitabine%20plus%20carboplatin%20in%20stage%20IIIB%20and%20IV%20non-small%20cell%20lung%20cancer%20%28NSCLC%29%3A%20a%20phase%20III%20randomized%20trial&amp;author=P%20Zatloukal&amp;author=L%20Petruzelka&amp;author=M%20Zemanova&amp;author=V%20Kolek&amp;author=J%20Skrickova&amp;author=M%20Pesek&amp;publication_year=2003&amp;journal=Lung%20Cancer&amp;volume=41&amp;pages=321-31">Google Scholar</a></div>
                        </div>
                     </li>
                     <li><span class="ref-label">(31)</span><a class="rev-xref-ref" href="#xref-ref-31-1" title="View reference (31) in text"
                           id="ref-31">↵</a><div class="cit ref-cit ref-journal" id="cit-99.11.847.31"
                             data-doi="10.1200/JCO.2003.12.046">
                           <div class="cit-metadata">
                              <ol class="cit-auth-list">
                                 <li><span class="cit-auth"><span class="cit-name-surname">Fossella</span>  <span class="cit-name-given-names">F</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Pereira</span>  <span class="cit-name-given-names">JR</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">von Pawel</span>  <span class="cit-name-given-names">J</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Pluzanska</span>  <span class="cit-name-given-names">A</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Gorbounova</span>  <span class="cit-name-given-names">V</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Kaukel</span>  <span class="cit-name-given-names">E</span></span>, 
                                 </li>
                                 <li><span class="cit-etal">et al</span></li>
                              </ol><cite>. <span class="cit-article-title">Randomized, multinational, phase III study of docetaxel plus platinum combinations vs vinorelbine plus cisplatin for advanced
                                    non-small cell lung cancer: The TAX 326 Study Group</span>. <abbr class="cit-jnl-abbrev">J Clin Oncol</abbr> <span class="cit-pub-date">2003</span>;<span class="cit-vol">21</span>:<span class="cit-fpage">3016</span>-<span class="cit-lpage">24</span>.</cite></div>
                           <div class="cit-extra"><a href="/cgi/ijlink?linkType=ABST&amp;journalCode=jco&amp;resid=21/16/3016"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-ijlinks"><span class="cit-reflinks-abstract">Abstract</span><span class="cit-sep cit-reflinks-variant-name-sep">/</span><span class="cit-reflinks-full-text"><span class="free-full-text">FREE </span>Full Text</span></a></div>
                        </div>
                     </li>
                     <li><span class="ref-label">(32)</span><a class="rev-xref-ref" href="#xref-ref-32-1" title="View reference (32) in text"
                           id="ref-32">↵</a><div class="cit ref-cit ref-journal" id="cit-99.11.847.32">
                           <div class="cit-metadata">
                              <ol class="cit-auth-list">
                                 <li><span class="cit-auth"><span class="cit-name-surname">Mazzanti</span>  <span class="cit-name-given-names">P</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Massacesi</span>  <span class="cit-name-given-names">C</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Rocchi</span>  <span class="cit-name-given-names">MBL</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Mattioli</span>  <span class="cit-name-given-names">R</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Lippe</span>  <span class="cit-name-given-names">P</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Trivisonne</span>  <span class="cit-name-given-names">R</span></span>, 
                                 </li>
                                 <li><span class="cit-etal">et al</span></li>
                              </ol><cite>. <span class="cit-article-title">Randomized, multicenter, phase II study of gemcitabine plus cisplatin versus gemcitabine plus carboplatin in patients with
                                    advanced non-small-cell lung cancer</span>. <abbr class="cit-jnl-abbrev">Lung Cancer</abbr> <span class="cit-pub-date">2003</span>;<span class="cit-vol">41</span>:<span class="cit-fpage">81</span>-<span class="cit-lpage">9</span>.</cite></div>
                           <div class="cit-extra"><a href="/external-ref?access_num=12826316&amp;link_type=MED"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-medline">Medline</a><a href="/external-ref?access_num=000184063900011&amp;link_type=ISI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">Web of Science</a><a target="_blank"
                                 href="http://scholar.google.com/scholar_lookup?title=Randomized%2C%20multicenter%2C%20phase%20II%20study%20of%20gemcitabine%20plus%20cisplatin%20versus%20gemcitabine%20plus%20carboplatin%20in%20patients%20with%20advanced%20non-small-cell%20lung%20cancer&amp;author=P%20Mazzanti&amp;author=C%20Massacesi&amp;author=MBL%20Rocchi&amp;author=R%20Mattioli&amp;author=P%20Lippe&amp;author=R%20Trivisonne&amp;publication_year=2003&amp;journal=Lung%20Cancer&amp;volume=41&amp;pages=81-9">Google Scholar</a></div>
                        </div>
                     </li>
                     <li><span class="ref-label">(33)</span><a class="rev-xref-ref" href="#xref-ref-33-1" title="View reference (33) in text"
                           id="ref-33">↵</a><div class="cit ref-cit ref-journal" id="cit-99.11.847.33"
                             data-doi="10.1016/S0169-5002(03)00280-0">
                           <div class="cit-metadata">
                              <ol class="cit-auth-list">
                                 <li><span class="cit-auth"><span class="cit-name-surname">Paccagnella</span>  <span class="cit-name-given-names">A</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Favaretto</span>  <span class="cit-name-given-names">A</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Oniga</span>  <span class="cit-name-given-names">F</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Barbieri</span>  <span class="cit-name-given-names">F</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Ceresoli</span>  <span class="cit-name-given-names">G</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Torri</span>  <span class="cit-name-given-names">W</span></span>, 
                                 </li>
                                 <li><span class="cit-etal">et al</span></li>
                              </ol><cite>. <span class="cit-article-title">Cisplatin versus carboplatin in combination with mitomycin and vinblastine in advanced non-small cell lung cancer. A multicenter,
                                    randomized phase III trial</span>. <abbr class="cit-jnl-abbrev">Lung Cancer</abbr> <span class="cit-pub-date">2004</span>;<span class="cit-vol">43</span>:<span class="cit-fpage">83</span>-<span class="cit-lpage">91</span>.</cite></div>
                           <div class="cit-extra"><a href="/external-ref?access_num=10.1016/S0169-5002(03)00280-0&amp;link_type=DOI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">CrossRef</a><a href="/external-ref?access_num=14698542&amp;link_type=MED"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-medline">Medline</a><a href="/external-ref?access_num=000188380700012&amp;link_type=ISI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">Web of Science</a><a target="_blank"
                                 href="http://scholar.google.com/scholar_lookup?title=Cisplatin%20versus%20carboplatin%20in%20combination%20with%20mitomycin%20and%20vinblastine%20in%20advanced%20non-small%20cell%20lung%20cancer.%20A%20multicenter%2C%20randomized%20phase%20III%20trial&amp;author=A%20Paccagnella&amp;author=A%20Favaretto&amp;author=F%20Oniga&amp;author=F%20Barbieri&amp;author=G%20Ceresoli&amp;author=W%20Torri&amp;publication_year=2004&amp;journal=Lung%20Cancer&amp;volume=43&amp;pages=83-91">Google Scholar</a></div>
                        </div>
                     </li>
                     <li><span class="ref-label">(34)</span><a class="rev-xref-ref" href="#xref-ref-34-1" title="View reference (34) in text"
                           id="ref-34">↵</a><div class="cit ref-cit ref-journal" id="cit-99.11.847.34">
                           <div class="cit-metadata">
                              <ol class="cit-auth-list">
                                 <li><span class="cit-auth"><span class="cit-name-surname">Calvert</span>  <span class="cit-name-given-names">AH</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Newell</span>  <span class="cit-name-given-names">DR</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Gumbrell</span>  <span class="cit-name-given-names">LA</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">O’Reilly</span>  <span class="cit-name-given-names">S</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Burnell</span>  <span class="cit-name-given-names">M</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Boxall</span>  <span class="cit-name-given-names">FE</span></span>, 
                                 </li>
                                 <li><span class="cit-etal">et al</span></li>
                              </ol><cite>. <span class="cit-article-title">Carboplatin dosage: prospective evaluation of a simple formula based on renal function</span>. <abbr class="cit-jnl-abbrev">J Clin Oncol</abbr> <span class="cit-pub-date">1989</span>;<span class="cit-vol">7</span>:<span class="cit-fpage">1748</span>-<span class="cit-lpage">56</span>.</cite></div>
                           <div class="cit-extra"><a href="/cgi/ijlink?linkType=ABST&amp;journalCode=jco&amp;resid=7/11/1748"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-ijlinks"><span class="cit-reflinks-abstract">Abstract</span></a></div>
                        </div>
                     </li>
                     <li><span class="ref-label">(35)</span><a class="rev-xref-ref" href="#xref-ref-35-1" title="View reference (35) in text"
                           id="ref-35">↵</a><div class="cit ref-cit ref-journal" id="cit-99.11.847.35"
                             data-doi="10.1200/JCO.2006.06.9591">
                           <div class="cit-metadata">
                              <ol class="cit-auth-list">
                                 <li><span class="cit-auth"><span class="cit-name-surname">Kris</span>  <span class="cit-name-given-names">MG</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Hesketh</span>  <span class="cit-name-given-names">PJ</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Somerfield</span>  <span class="cit-name-given-names">MR</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Petra</span>  <span class="cit-name-given-names">F</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Clark-Snow</span>  <span class="cit-name-given-names">R</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Koeller</span>  <span class="cit-name-given-names">JM</span></span>, 
                                 </li>
                                 <li><span class="cit-etal">et al</span></li>
                              </ol><cite>. <span class="cit-article-title">American Society of Clinical Oncology guideline for antiemetics in oncology: update 2006</span>. <abbr class="cit-jnl-abbrev">J Clin Oncol</abbr> <span class="cit-pub-date">2006</span>;<span class="cit-vol">24</span>:<span class="cit-fpage">2932</span>-<span class="cit-lpage">47</span>.</cite></div>
                           <div class="cit-extra"><a href="/cgi/ijlink?linkType=ABST&amp;journalCode=jco&amp;resid=24/18/2932"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-ijlinks"><span class="cit-reflinks-abstract">Abstract</span><span class="cit-sep cit-reflinks-variant-name-sep">/</span><span class="cit-reflinks-full-text"><span class="free-full-text">FREE </span>Full Text</span></a></div>
                        </div>
                     </li>
                     <li><span class="ref-label">(36)</span><a class="rev-xref-ref" href="#xref-ref-36-1" title="View reference (36) in text"
                           id="ref-36">↵</a><div class="cit ref-cit ref-journal" id="cit-99.11.847.36">
                           <div class="cit-metadata">
                              <ol class="cit-auth-list">
                                 <li><span class="cit-auth"><span class="cit-name-surname">Chan</span>  <span class="cit-name-given-names">AM</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Mao</span>  <span class="cit-name-given-names">AJ</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Wu</span>  <span class="cit-name-given-names">T</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Zhang</span>  <span class="cit-name-given-names">Y</span></span></li>
                              </ol><cite>. <span class="cit-article-title">Meta-analysis comparing carboplatin and cisplatin-based chemotherapy in advanced non-small cell lung cancer</span>. <abbr class="cit-jnl-abbrev">Proc Am Soc Clin Oncol</abbr> <span class="cit-pub-date">2005</span>;<span class="cit-vol">24</span>. <span class="cit-comment">abstract 7218.</span></cite></div>
                           <div class="cit-extra"><a target="_blank"
                                 href="http://scholar.google.com/scholar_lookup?title=Meta-analysis%20comparing%20carboplatin%20and%20cisplatin-based%20chemotherapy%20in%20advanced%20non-small%20cell%20lung%20cancer&amp;author=AM%20Chan&amp;author=AJ%20Mao&amp;author=T%20Wu&amp;author=Y%20Zhang&amp;publication_year=2005&amp;journal=Proc%20Am%20Soc%20Clin%20Oncol&amp;volume=24">Google Scholar</a></div>
                        </div>
                     </li>
                     <li><span class="ref-label">(37)</span><a class="rev-xref-ref" href="#xref-ref-37-1" title="View reference (37) in text"
                           id="ref-37">↵</a><div class="cit ref-cit ref-journal" id="cit-99.11.847.37"
                             data-doi="10.1200/JCO.2004.06.924">
                           <div class="cit-metadata">
                              <ol class="cit-auth-list">
                                 <li><span class="cit-auth"><span class="cit-name-surname">Piedbois</span>  <span class="cit-name-given-names">P</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Buyse</span>  <span class="cit-name-given-names">M</span></span></li>
                              </ol><cite>. <span class="cit-article-title">Meta-analyses based on abstracted data: a step in the right direction, but only a first step</span>. <abbr class="cit-jnl-abbrev">J Clin Oncol</abbr> <span class="cit-pub-date">2004</span>;<span class="cit-vol">22</span>:<span class="cit-fpage">3839</span>-<span class="cit-lpage">41</span>.</cite></div>
                           <div class="cit-extra"><a href="/cgi/ijlink?linkType=FULL&amp;journalCode=jco&amp;resid=22/19/3839"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-ijlinks"><span class="cit-reflinks-full-text"><span class="free-full-text">FREE </span>Full Text</span></a></div>
                        </div>
                     </li>
                     <li><span class="ref-label">(38)</span><a class="rev-xref-ref" href="#xref-ref-38-1" title="View reference (38) in text"
                           id="ref-38">↵</a><div class="cit ref-cit ref-journal" id="cit-99.11.847.38"
                             data-doi="10.1016/j.lungcan.2004.10.014">
                           <div class="cit-metadata">
                              <ol class="cit-auth-list">
                                 <li><span class="cit-auth"><span class="cit-name-surname">Le Chevalier</span>  <span class="cit-name-given-names">T</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Scagliotti</span>  <span class="cit-name-given-names">G</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Natale</span>  <span class="cit-name-given-names">R</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Danson</span>  <span class="cit-name-given-names">S</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Rosell</span>  <span class="cit-name-given-names">R</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Stahel</span>  <span class="cit-name-given-names">R</span></span>, 
                                 </li>
                                 <li><span class="cit-etal">et al</span></li>
                              </ol><cite>. <span class="cit-article-title">Efficacy of gemcitabine plus platinum chemotherapy compared with other platinum containing regimens in advanced non-small-cell
                                    lung cancer: a meta-analysis of survival outcomes</span>. <abbr class="cit-jnl-abbrev">Lung Cancer</abbr> <span class="cit-pub-date">2005</span>;<span class="cit-vol">47</span>:<span class="cit-fpage">69</span>-<span class="cit-lpage">80</span>.</cite></div>
                           <div class="cit-extra"><a href="/external-ref?access_num=10.1016/j.lungcan.2004.10.014&amp;link_type=DOI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">CrossRef</a><a href="/external-ref?access_num=15603856&amp;link_type=MED"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-medline">Medline</a><a href="/external-ref?access_num=000226575100008&amp;link_type=ISI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">Web of Science</a><a target="_blank"
                                 href="http://scholar.google.com/scholar_lookup?title=Efficacy%20of%20gemcitabine%20plus%20platinum%20chemotherapy%20compared%20with%20other%20platinum%20containing%20regimens%20in%20advanced%20non-small-cell%20lung%20cancer%3A%20a%20meta-analysis%20of%20survival%20outcomes&amp;author=T%20Le%20Chevalier&amp;author=G%20Scagliotti&amp;author=R%20Natale&amp;author=S%20Danson&amp;author=R%20Rosell&amp;author=R%20Stahel&amp;publication_year=2005&amp;journal=Lung%20Cancer&amp;volume=47&amp;pages=69-80">Google Scholar</a></div>
                        </div>
                     </li>
                     <li><span class="ref-label">(39)</span><a class="rev-xref-ref" href="#xref-ref-39-1" title="View reference (39) in text"
                           id="ref-39">↵</a><div class="cit ref-cit ref-journal" id="cit-99.11.847.39">
                           <div class="cit-metadata">
                              <ol class="cit-auth-list">
                                 <li><span class="cit-auth"><span class="cit-name-surname">Pignon</span>  <span class="cit-name-given-names">JP</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Tribodet</span>  <span class="cit-name-given-names">H</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Scagliotti</span>  <span class="cit-name-given-names">GV</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Douillard</span>  <span class="cit-name-given-names">JY</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Shepherd</span>  <span class="cit-name-given-names">FA</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Stephens</span>  <span class="cit-name-given-names">RJ</span></span>, 
                                 </li>
                                 <li><span class="cit-etal">et al</span></li>
                              </ol><cite>. <span class="cit-article-title">Lung Adjuvant Cisplatin Evaluation (LACE): a pooled analysis of five randomized clinical trials including 4,584 patients</span>. <abbr class="cit-jnl-abbrev">Proc Am Soc Clin Oncol</abbr> <span class="cit-pub-date">2006</span>;<span class="cit-vol">24</span>. <span class="cit-comment">abstract 7008.</span></cite></div>
                           <div class="cit-extra"><a target="_blank"
                                 href="http://scholar.google.com/scholar_lookup?title=Lung%20Adjuvant%20Cisplatin%20Evaluation%20%28LACE%29%3A%20a%20pooled%20analysis%20of%20five%20randomized%20clinical%20trials%20including%204%2C584%20patients&amp;author=JP%20Pignon&amp;author=H%20Tribodet&amp;author=GV%20Scagliotti&amp;author=JY%20Douillard&amp;author=FA%20Shepherd&amp;author=RJ%20Stephens&amp;publication_year=2006&amp;journal=Proc%20Am%20Soc%20Clin%20Oncol&amp;volume=24">Google Scholar</a></div>
                        </div>
                     </li>
                     <li><span class="ref-label">(40)</span><a class="rev-xref-ref" href="#xref-ref-40-1" title="View reference (40) in text"
                           id="ref-40">↵</a><div class="cit ref-cit ref-journal" id="cit-99.11.847.40">
                           <div class="cit-metadata">
                              <ol class="cit-auth-list">
                                 <li><span class="cit-auth"><span class="cit-name-surname">Strauss</span>  <span class="cit-name-given-names">GM</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Herndon</span>  <span class="cit-name-given-names">JE</span>  <span class="cit-name-suffix">II</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Maddaus</span>  <span class="cit-name-given-names">MA</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Johnstone</span>  <span class="cit-name-given-names">DW</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Johnson</span>  <span class="cit-name-given-names">EA</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Watson</span>  <span class="cit-name-given-names">DM</span></span>, 
                                 </li>
                                 <li><span class="cit-etal">et al</span></li>
                              </ol><cite>. <span class="cit-article-title">Adjuvant chemotherapy in stage IB non-small cell lung cancer (NSCLC): update of cancer and Leukemia Group B (CALGB) protocol
                                    9633</span>. <abbr class="cit-jnl-abbrev">Proc Am Soc Clin Oncol</abbr> <span class="cit-pub-date">2006</span>;<span class="cit-vol">24</span>. <span class="cit-comment">abstract 7007.</span></cite></div>
                           <div class="cit-extra"><a target="_blank"
                                 href="http://scholar.google.com/scholar_lookup?title=Adjuvant%20chemotherapy%20in%20stage%20IB%20non-small%20cell%20lung%20cancer%20%28NSCLC%29%3A%20update%20of%20cancer%20and%20Leukemia%20Group%20B%20%28CALGB%29%20protocol%209633&amp;author=GM%20Strauss&amp;author=JE%20Herndon&amp;author=MA%20Maddaus&amp;author=DW%20Johnstone&amp;author=EA%20Johnson&amp;author=DM%20Watson&amp;publication_year=2006&amp;journal=Proc%20Am%20Soc%20Clin%20Oncol&amp;volume=24">Google Scholar</a></div>
                        </div>
                     </li>
                  </ol>
               </div><span class="highwire-journal-article-marker-end"></span></div>
            <div id="related">
               <h2>Related articles</h2>
               <ul class="related-list">
                  <div class="cit">
                     <div class="cit-metadata"><span class="cit-first-element cit-section">IN THIS ISSUE<span class="cit-sep cit-sep-after-article-section">:</span> </span><span class="cit-title">IN THIS ISSUE </span> <cite><abbr title="Journal of the National Cancer Institute" class="site-title">JNCI J Natl Cancer Inst</abbr> <span class="cit-print-date"><span class="cit-sep cit-sep-before-article-print-date">(</span>2007<span class="cit-sep cit-sep-after-article-print-date">)</span> </span><span class="cit-vol">99 </span><span class="cit-issue"><span class="cit-sep cit-sep-before-article-issue">(</span>11<span class="cit-sep cit-sep-after-article-issue">):</span> </span><span class="cit-pages"><span class="cit-first-page">825</span> </span><span class="cit-doi"><span class="cit-sep cit-sep-before-article-doi"> doi:</span>10.1093/jnci/djk225 </span><span class="cit-online-date"><span class="cit-sep cit-sep-before-article-online-date">First published online </span>June 5, 2007 </span></cite>  
                     </div>
                     <div class="cit-extra"><span class="accesscheck jnci;99/11/825 pdf_extract,full,reprint"></span> 
                        <ul class="cit-views">
                           <li class="first-item"><a href="/content/99/11/825.1.extract" rel="extract">Extract</a></li>
                           <li><a href="/content/99/11/825.1.full" rel="full-text">Full Text (HTML)</a></li>
                           <li><a href="/content/99/11/825.1.full.pdf+html" rel="full-text.pdf">Full Text (PDF)</a></li>
                           <li class="last-item"><a href="/content/99/11/825.1/suppl/DC1" rel="supplemental-data"
                                 class="dslink-japanese-translation">Japanese Translation</a></li>
                        </ul>  
                     </div> 
                  </div>
                  <div class="cit">
                     <div class="cit-metadata"><span class="cit-first-element cit-section">MEMO TO THE MEDIA<span class="cit-sep cit-sep-after-article-section">:</span> </span><ul class="cit-auth-list">
                           <li class="first-item"><span class="cit-auth cit-auth-type-author">Liz Savage</span></li>  
                        </ul><span class="cit-title">Press Release<span class="cit-sep cit-sep-after-article-title">: </span><span class="cit-subtitle">Cisplatin is More Effective than Carboplatin for Treating Non–Small-Cell Lung Cancer </span> </span> <cite><abbr title="Journal of the National Cancer Institute" class="site-title">JNCI J Natl Cancer Inst</abbr> <span class="cit-print-date"><span class="cit-sep cit-sep-before-article-print-date">(</span>2007<span class="cit-sep cit-sep-after-article-print-date">)</span> </span><span class="cit-vol">99 </span><span class="cit-issue"><span class="cit-sep cit-sep-before-article-issue">(</span>11<span class="cit-sep cit-sep-after-article-issue">):</span> </span><span class="cit-pages"><span class="cit-first-page">825</span> </span><span class="cit-doi"><span class="cit-sep cit-sep-before-article-doi"> doi:</span>10.1093/jnci/djk234 </span><span class="cit-online-date"><span class="cit-sep cit-sep-before-article-online-date">First published online </span>June 5, 2007 </span></cite>  
                     </div>
                     <div class="cit-extra"><span class="accesscheck jnci;99/11/825-b extract,full"></span> 
                        <ul class="cit-views">
                           <li class="first-item"><a href="/content/99/11/825.3.extract" rel="extract">Extract</a></li>
                           <li class="last-item"><a href="/content/99/11/825.3.full" rel="full-text">Full Text (HTML)</a></li>
                        </ul>  
                     </div> 
                  </div>
               </ul>
            </div><span id="related-urls"></span></div>
         <div id="col-2">
            
            <div class="article-nav sidebar-nav">
               <a href="/content/99/11/838.short" title="Previous article" class="previous">« Previous</a><span class="article-nav-sep"> | </span><a href="/content/99/11/858.short" title="Next article" class="next">Next Article »</a>
               
               <span class="toc-link">
                  				<a href="/content/99/11.toc" title="Table of Contents">Table of Contents</a>
                  			</span>
               
               
            </div>
            <div class="content-box" id="article-cb-main">
               <div class="cb-contents">
                  <h3 class="cb-contents-header"><span>This Article</span></h3>
                  <div class="cb-section cb-slug">
                     <ol>
                        <li>
                           <div id="slugline">
                              
                              <cite>
                                 <abbr title="JNCI Journal of the National Cancer Institute" class="slug-jnl-abbrev">
                                    <nlm:abbrev-journal-title xmlns:nlm="http://schema.highwire.org/NLM/Journal" abbrev-type="publisher">JNCI J Natl Cancer Inst</nlm:abbrev-journal-title></abbr><span class="slug-pub-date" itemprop="datePublished">
                                    (2007) 
                                    </span>
                                 
                                 <span class="slug-vol">
                                    99
                                    </span><span class="slug-issue">
                                    (11):
                                    </span><span class="slug-pages">
                                    847-857.
                                    </span>
                                 <span class="slug-doi-wrapper">
                                    
                                    doi:
                                    
                                    <span title="10.1093/jnci/djk196" class="slug-doi">10.1093/jnci/djk196</span>
                                    </span>
                                 </cite>
                              
                              
                              
                              
                              
                              
                              
                              
                              
                              
                              
                              
                           </div>
                        </li>
                     </ol>
                  </div>
                  <div class="cb-section cb-views">
                     <ol>
                        <li class="abstract-view-link primary"><a href="/content/99/11/847.abstract" rel="view-abstract">Abstract</a><span class="free">Free</span></li>
                        <li class="notice full-text-view-link"><span class="variant-indicator">» <span>Full Text (HTML)</span></span><span class="free">Free</span></li>
                        <li class="notice full-text-pdf-view-link"><a href="/content/99/11/847.full.pdf+html" rel="view-full-text.pdf">Full Text (PDF)</a><span class="free">Free</span></li>
                     </ol>
                  </div>
                  <div class="cb-section collapsible" id="cb-art-cat">
                     <h4 class="cb-section-header"><span>Classifications</span></h4>
                     <ol>
                        <li>
                           <ul class="subject-headings last-child">
                              <li><a class="tocsection-search"
                                    href="/search?tocsectionid=ARTICLES&amp;sortspec=date&amp;submit=Submit">Article</a></li>
                           </ul>
                        </li>
                     </ol>
                  </div>
                  <div class="cb-section collapsible" id="cb-art-svcs">
                     <h4 class="cb-section-header"><span>Services</span></h4>
                     <ol>
                        <li class="usage-stats-link icon-link"><a href="/articleusage?gca=jnci;99/11/847" rel="nofollow">Article metrics</a></li>
                        <li class="alert-link icon-link"><a href="/cgi/alerts/ctalert?alertType=citedby&amp;addAlert=cited_by&amp;cited_by_criteria_resid=jnci%3B99%2F11%2F847&amp;saveAlert=no&amp;return-type=article&amp;return_url=http://jnci.oxfordjournals.org/content/99/11/847.full">Alert me when cited</a></li>
                        <li class="alert-link icon-link"><a href="/cgi/alerts/ctalert?alertType=correction&amp;addAlert=correction&amp;correction_criteria_value=99/11/847&amp;saveAlert=no&amp;return-type=article&amp;return_url=http://jnci.oxfordjournals.org/content/99/11/847.full">Alert me if corrected</a></li>
                        <li class="similar-link"><a href="/search?qbe=jnci%3B99%2F11%2F847&amp;citation=Ardizzoni%20et%20al.%2099%20%2811%29:%20847&amp;submit=yes">Find similar articles</a></li>
                        <li class="similar-link"><a href="/external-ref?access_num=jnci%3B99%2F11%2F847&amp;link_type=ISI_RELATEDRECORDS"
                              id="cb-isi-similar-articles"
                              class="similar-link">Similar articles in Web of Science</a></li>
                        <li class="similar-link"><a href="/external-ref?access_num=17551145&amp;link_type=MED_NBRS"
                              class="similar-link">Similar articles in PubMed</a></li>
                        <li class="folder-link icon-link"><a href="/cgi/folders?action=addtofolder&amp;wherefrom=JOURNALS&amp;wrapped_id=jnci%3B99%2F11%2F847">Add to my archive</a></li>
                        <li class="cit-man-link icon-link cite-link"><a href="/citmgr?gca=jnci%3B99%2F11%2F847">Download citation</a></li>
                        <li><a class="request-permissions"
                              href="https://s100.copyright.com/AppDispatchServlet?publisherName=oup&amp;publication=jnci&amp;title=Cisplatin-%20Versus%20Carboplatin-Based%20Chemotherapy%20in%20First-Line%20Treatment%20of%20Advanced%20Non%E2%80%93Small-Cell%20Lung%20Cancer%3A%20An%20Individual%20Patient%20Data%20Meta-analysis%3A%20&amp;publicationDate=06%2F06%2F2007&amp;author=Andrea%20Ardizzoni%2C%20Luca%20Boni%2C%20Marcello%20Tiseo%2C%20Frank%20V.%20Fossella%2C%20Joan%20H.%20Schiller%2C%20Marianne%20Paesmans%2C%20Davorin%20Radosavljevic%2C%20Adriano%20Paccagnella%2C%20Petr%20Zatloukal%2C%20Paola%20Mazzanti%2C%20Donald%20Bisset%2C%20Rafael%20Rosell&amp;copyright=Oxford%20University%20Press&amp;contentID=10.1093%2Fjnci%2Fdjk196&amp;volumeNum=99&amp;issueNum=11&amp;startPage=847&amp;endPage=857&amp;orderBeanReset=true"
                              target="_blank">Request Permissions</a></li>
                     </ol>
                  </div>
                  <div class="cb-section collapsible default-closed" id="cb-art-cit">
                     <h4 class="cb-section-header"><span>Citing Articles</span></h4>
                     <ol>
                        <li class="hw-citing-link"><a href="/content/99/11/847.full?cited-by=yes&amp;legid=jnci;99/11/847#cited-by"
                              id="cb-hw-citing-articles">Load citing article information</a></li>
                        <li><a href="/cgi/crossref-forward-links/99/11/847" rel="external-nw"
                              id="cb-crossref-citing-articles">Citing articles via CrossRef</a></li>
                        <li><a href="/scopus-links/jnci/99/11/847?access_num=/jnci/99/11/847"
                              rel="external-nw"
                              id="cb-scopus-citing-articles">Citing articles via Scopus</a></li>
                        <li><a href="/external-ref?access_num=%2Fjnci%2F99%2F11%2F847&amp;link_type=ISI_CITING&amp;accnum_type=native"
                              rel="external-nw"
                              id="cb-isi-citing-articles">Citing articles via Web of Science</a></li>
                        <li><a href="/external-ref?access_num=http://jnci.oxfordjournals.org/content/99/11/847.abstract&amp;link_type=GOOGLESCHOLAR">Citing articles via Google Scholar</a></li>
                     </ol>
                  </div>
                  <div class="cb-section collapsible default-closed" id="cb-art-gs">
                     <h4 class="cb-section-header"><span>Google Scholar</span></h4>
                     <ol>
                        <li class="cb-art-gs-auth author-link"><a href="http://scholar.google.com/scholar?q=%22author%3AArdizzoni%20author%3AA.%22"
                              class="cb-art-gs-auth author-link">Articles by  Ardizzoni, A.</a></li>
                        <li class="cb-art-gs-auth author-link"><a href="http://scholar.google.com/scholar?q=%22author%3ARosell%20author%3AR.%22"
                              class="cb-art-gs-auth author-link">Articles by  Rosell, R.</a></li>
                        <li class="cb-art-gs-rel similar-link"><a href="/external-ref?access_num=http://jnci.oxfordjournals.org/content/99/11/847.abstract&amp;link_type=GOOGLESCHOLARRELATED">Search for related content</a></li>
                     </ol>
                  </div>
                  <div class="cb-section collapsible default-closed" id="cb-art-pm">
                     <h4 class="cb-section-header"><span>PubMed</span></h4>
                     <ol>
                        <li class="cb-art-pm-cite cite-link icon-link"><a href="/external-ref?access_num=17551145&amp;link_type=PUBMED"
                              class="cb-art-pm-cite cite-link icon-link">PubMed citation</a></li>
                        <li class="cb-art-pm-auth author-link"><a href="/external-ref?access_num=Ardizzoni%20A&amp;link_type=AUTHORSEARCH"
                              class="cb-art-pm-auth author-link">Articles by  Ardizzoni, A.</a></li>
                        <li class="cb-art-pm-auth author-link"><a href="/external-ref?access_num=Boni%20L&amp;link_type=AUTHORSEARCH"
                              class="cb-art-pm-auth author-link">Articles by  Boni, L.</a></li>
                        <li class="cb-art-pm-auth author-link"><a href="/external-ref?access_num=Tiseo%20M&amp;link_type=AUTHORSEARCH"
                              class="cb-art-pm-auth author-link">Articles by  Tiseo, M.</a></li>
                        <li class="cb-art-pm-auth author-link"><a href="/external-ref?access_num=Fossella%20FV&amp;link_type=AUTHORSEARCH"
                              class="cb-art-pm-auth author-link">Articles by  Fossella, F. V.</a></li>
                        <li class="cb-art-pm-auth author-link"><a href="/external-ref?access_num=Schiller%20JH&amp;link_type=AUTHORSEARCH"
                              class="cb-art-pm-auth author-link">Articles by  Schiller, J. H.</a></li>
                        <li class="cb-art-pm-auth author-link"><a href="/external-ref?access_num=Paesmans%20M&amp;link_type=AUTHORSEARCH"
                              class="cb-art-pm-auth author-link">Articles by  Paesmans, M.</a></li>
                        <li class="cb-art-pm-auth author-link"><a href="/external-ref?access_num=Radosavljevic%20D&amp;link_type=AUTHORSEARCH"
                              class="cb-art-pm-auth author-link">Articles by  Radosavljevic, D.</a></li>
                        <li class="cb-art-pm-auth author-link"><a href="/external-ref?access_num=Paccagnella%20A&amp;link_type=AUTHORSEARCH"
                              class="cb-art-pm-auth author-link">Articles by  Paccagnella, A.</a></li>
                        <li class="cb-art-pm-auth author-link"><a href="/external-ref?access_num=Zatloukal%20P&amp;link_type=AUTHORSEARCH"
                              class="cb-art-pm-auth author-link">Articles by  Zatloukal, P.</a></li>
                        <li class="cb-art-pm-auth author-link"><a href="/external-ref?access_num=Mazzanti%20P&amp;link_type=AUTHORSEARCH"
                              class="cb-art-pm-auth author-link">Articles by  Mazzanti, P.</a></li>
                        <li class="cb-art-pm-auth author-link"><a href="/external-ref?access_num=Bisset%20D&amp;link_type=AUTHORSEARCH"
                              class="cb-art-pm-auth author-link">Articles by  Bisset, D.</a></li>
                        <li class="cb-art-pm-auth author-link"><a href="/external-ref?access_num=Rosell%20R&amp;link_type=AUTHORSEARCH"
                              class="cb-art-pm-auth author-link">Articles by  Rosell, R.</a></li>
                     </ol>
                  </div>
                  <div class="cb-section collapsible default-closed" id="cb-art-rel">
                     <h4 class="cb-section-header"><span>Related Content</span></h4>
                     <ol>
                        <li><a href="#related">Related articles in this journal</a></li>
                        <li><a href="/content/99/11/847.full?related-urls=yes&amp;legid=jnci;99/11/847#related-urls"
                              id="cb-related-urls">Load related web page information</a></li>
                     </ol>
                  </div>
                  <div class="cb-section collapsible" id="cb-art-soc">
                     <h4 class="cb-section-header"><span>Share</span></h4>
                     <ol>
                        <li><a href="/email?gca=jnci%3B99%2F11%2F847&amp;current-view-path=/content/99/11/847.full">
                              Email this article</a></li>
                        <li>
                           <div class="social-bookmarking">
                              
                              <ul class="social-bookmark-links">
                                 <li class="social-bookmarking-item social-bookmarking-item-citeulike"><a href="/external-ref?tag_url=http://jnci.oxfordjournals.org/cgi/content/long/99/11/847&amp;title=Cisplatin-%20Versus%20Carboplatin-Based%20Chemotherapy%20in%20First-Line%20Treatment%20of%20Advanced%20Non%E2%80%93Small-Cell%20Lung%20Cancer%3A%20An%20Individual%20Patient%20Data%20Meta-analysis+--+Ardizzoni%20et%20al.%2099%20%2811%29%3A%20847+--+Journal%20of%20the%20National%20Cancer%20Institute&amp;doi=10.1093/jnci/djk196&amp;link_type=CITEULIKE"><img src="/shared/img/common/social-bookmarking/citeulike.gif"
                                            alt="Add to CiteULike"
                                            title="CiteULike" /></a><span class="soc-bm-link-text">CiteULike</span></li>
                                 <li class="social-bookmarking-item social-bookmarking-item-delicious"><a href="/external-ref?tag_url=http://jnci.oxfordjournals.org/cgi/content/long/99/11/847&amp;title=Cisplatin-%20Versus%20Carboplatin-Based%20Chemotherapy%20in%20First-Line%20Treatment%20of%20Advanced%20Non%E2%80%93Small-Cell%20Lung%20Cancer%3A%20An%20Individual%20Patient%20Data%20Meta-analysis+--+Ardizzoni%20et%20al.%2099%20%2811%29%3A%20847+--+Journal%20of%20the%20National%20Cancer%20Institute&amp;doi=10.1093/jnci/djk196&amp;link_type=DEL_ICIO_US"><img src="/shared/img/common/social-bookmarking/delicious.gif"
                                            alt="Add to Delicious"
                                            title="Delicious" /></a><span class="soc-bm-link-text">Delicious</span></li>
                                 <li class="social-bookmarking-item social-bookmarking-item-facebook"><a href="/external-ref?tag_url=http://jnci.oxfordjournals.org/cgi/content/short/99/11/847&amp;title=Cisplatin-%20Versus%20Carboplatin-Based%20Chemotherapy%20in%20First-Line%20Treatment%20of%20Advanced%20Non%E2%80%93Small-Cell%20Lung%20Cancer%3A%20An%20Individual%20Patient%20Data%20Meta-analysis+--+Ardizzoni%20et%20al.%2099%20%2811%29%3A%20847+--+Journal%20of%20the%20National%20Cancer%20Institute&amp;doi=10.1093/jnci/djk196&amp;link_type=FACEBOOK"
                                       class="sb-facebook"
                                       rel="external-nw"><img src="/shared/img/common/social-bookmarking/facebook.gif" alt="Add to Facebook"
                                            title="Facebook" /></a><span class="soc-bm-link-text">Facebook</span></li>
                                 <li class="social-bookmarking-item social-bookmarking-item-googleplus"><a href="/external-ref?tag_url=http://jnci.oxfordjournals.org/cgi/content/long/99/11/847&amp;title=Cisplatin-%20Versus%20Carboplatin-Based%20Chemotherapy%20in%20First-Line%20Treatment%20of%20Advanced%20Non%E2%80%93Small-Cell%20Lung%20Cancer%3A%20An%20Individual%20Patient%20Data%20Meta-analysis+--+Ardizzoni%20et%20al.%2099%20%2811%29%3A%20847+--+Journal%20of%20the%20National%20Cancer%20Institute&amp;doi=10.1093/jnci/djk196&amp;link_type=GOOGLEPLUS&amp;log_only=yes"><img src="/shared/img/common/social-bookmarking/googleplus.jpg" alt="Add to Google+"
                                            title="Google+" /></a><span class="soc-bm-link-text">Google+</span></li>
                                 <li class="social-bookmarking-item social-bookmarking-item-mendeley"><a href="/external-ref?tag_url=http://jnci.oxfordjournals.org/cgi/content/long/99/11/847&amp;title=Cisplatin-%20Versus%20Carboplatin-Based%20Chemotherapy%20in%20First-Line%20Treatment%20of%20Advanced%20Non%E2%80%93Small-Cell%20Lung%20Cancer%3A%20An%20Individual%20Patient%20Data%20Meta-analysis+--+Ardizzoni%20et%20al.%2099%20%2811%29%3A%20847+--+Journal%20of%20the%20National%20Cancer%20Institute&amp;doi=10.1093/jnci/djk196&amp;link_type=MENDELEY"><img src="/shared/img/common/social-bookmarking/mendeley.gif" alt="Add to Mendeley"
                                            title="Mendeley" /></a><span class="soc-bm-link-text">Mendeley</span></li>
                                 <li class="social-bookmarking-item social-bookmarking-item-twitter"><a href="/external-ref?tag_url=http://jnci.oxfordjournals.org/cgi/content/long/99/11/847&amp;title=Cisplatin-%20Versus%20Carboplatin-Based%20Chemotherapy%20in%20First-Line%20Treatment%20of%20Advanced%20Non%E2%80%93Small-Cell%20Lung%20Cancer%3A%20An%20Individual%20Patient%20Data%20Meta-analysis+--+Ardizzoni%20et%20al.%2099%20%2811%29%3A%20847+--+Journal%20of%20the%20National%20Cancer%20Institute&amp;doi=10.1093/jnci/djk196&amp;link_type=TWITTER"><img src="/shared/img/common/social-bookmarking/twitter.gif" alt="Add to Twitter"
                                            title="Twitter" /></a><span class="soc-bm-link-text">Twitter</span></li>
                              </ul>
                              
                              <p class="social-bookmarking-help"><a href="/help/social_bookmarks.dtl">What's this?</a></p>
                              
                           </div>
                        </li>
                     </ol>
                  </div>
               </div>
            </div>
            
            
            <div class="content-box" id="article-dyn-nav">
               <div class="cb-contents">
                  <h3 class="cb-contents-header"><span>Navigate This Article</span></h3>
                  <div class="cb-section" id="cb-art-nav">
                     <ol>
                        <li><a href="#content-block">Top</a></li>
                        <li><a href="#abstract-1">Abstract</a></li>
                        <li><a href="#sec-11">Materials and Methods</a></li>
                        <li><a href="#sec-16">Results</a></li>
                        <li><a href="#sec-20">Discussion</a></li>
                        <li><a href="#fn-group-1">Footnotes</a></li>
                        <li><a href="#ref-list-1">References</a></li>
                     </ol>
                  </div>
               </div>
            </div>
            
         </div>
         <div id="col-3">
            
            <div id="col-3-qs" class="sidebar-qs">
               
               
               <form class="searchbox" action="/search" method="get">
                  <p>Search this journal:</p>
                  <div>
                     	
                     	
                     	<input value="" type="text" name="fulltext" id="header-qs-input" />
                     <input type="hidden" name="submit" value="yes" />
                     
                     <input class="inline_button" type="image" alt="Go" src="/publisher/img/buttons/go.gif" />
                     
                     <div class="adv-search-link"><a href="/search">Advanced »</a></div>
                     
                     
                  </div>
               </form>
               
            </div>
            <div class="cb-contents">
               
               <div id="sidebar-current-issue" class="content-box">
                  	
                  <h3 class="cb-contents-header">Current Issue</h3>
                  	
                  <div class="cb-section">
                     	  
                     <ol>
                        <li>
                           	      <a href="/content/current"><span>
                                 		  <span class="current-issue-date">
                                    October 2015
                                    </span><span class="toc-citation-volume">
                                    
                                    107
                                    </span><span class="toc-citation-issue">(10)</span>
                                 		  
                                 		</span></a>
                           	    
                        </li>
                     </ol>
                     	
                  </div>
                  	
                  <div class="cb-section">
                     	  
                     <ol>
                        <li>
                           <a href="/content/current"><img src="/content/107/10.cover.gif" alt="JNCI J Natl Cancer Inst" id="cover" /></a>
                           
                        </li>
                     </ol>
                     	
                  </div>
                  	
                  <div class="cb-section sidebar-etoc-link">
                     	  
                     <ol>
                        <li><a href="/cgi/alerts/etoc">Alert me to new issues</a></li>
                     </ol>
                     	
                  </div>
                  
               </div>
               
            </div>
            
            <div id="second">
               
               <div class="ad_hidden" id="oas_right1">
                  <iframe id="id_advertframe_right1"
                          src="/resource/htmlfiles/advert.html?p=Right1&amp;u=jnci.oxfordjournals.org/content/99/11/847.full"
                          width="0"
                          height="0"
                          frameborder="0"
                          scrolling="no"
                          class="resize_ad"></iframe>
                  
               </div>
               
               <div class="features">
                  
                  <div class="feature separator_after first">
                     
                     <h2 id="the_journal" title="The Journal"><span>The Journal</span></h2>
                     
                     <ul class="emphasised">
                        <li>
                           <a href="http://www.oxfordjournals.org/our_journals/jnci/about.html" rel=""
                              title="About this journal">About this journal</a>
                           
                        </li>
                        <li>
                           <a href="http://www.oxfordjournals.org/our_journals/jnci/contact_us.html" rel=""
                              title="Contact Us">Contact Us</a>
                           
                        </li>
                        <li>
                           <a href="http://www.oxfordjournals.org/access_purchase/rights_permissions.html"
                              rel=""
                              title="Rights &amp; Permissions">Rights &amp; Permissions</a>
                           
                        </li>
                        <li>
                           <a href="HTTP://www.oxfordjournals.org/access_purchase/dispatch_dates.html#JNCI.JP"
                              rel=""
                              title="Dispatch date of next issue">Dispatch date of next issue</a>
                           
                        </li>
                        <li>
                           <a href="http://publicationethics.org/" rel=""
                              title="This journal is a member of the Committee on Publication Ethics (COPE)">This journal is a member of the Committee on Publication Ethics (COPE)</a>
                           
                        </li>
                        <li>
                           <a href="http://www.oxfordjournals.org/mobile_faqs.html" rel=""
                              title="We are mobile – find out more">We are mobile – find out more</a>
                           
                        </li>
                        <li>
                           <a href="http://medicine-and-health-careernetwork.oxfordjournals.org/jobseeker/search/results/?t730=&amp;t732=469986&amp;t731=&amp;t733=&amp;t735=&amp;t737=&amp;max=25&amp;site_id=20102"
                              rel=""
                              title="Journals Career Network">Journals Career Network</a>
                           
                        </li>
                     </ul>
                     
                     <p>
                        <a href="http://www.oxfordjournals.org/our_journals/jnci/episodes_2012.html">
                           <img alt="Podcast Logo" style="float:left"
                                src="http://www.oxfordjournals.org/podcasts/podcast_icon_35x35.gif" />JNCI Podcast</a>
                        <br />
                        <br />
                        
                     </p>
                     
                  </div>
                  
                  <div class="feature separator_after">
                     
                     <h3>Connect with us!</h3>
                     <a href="https://twitter.com/JNCI_Now">
                        <img class="small_margin" alt="Connect with us on Twitter!"
                             src="http://www.oxfordjournals.org/our_journals/phisci/connect_twitter.png"
                             style="vertical-align: top; float: left; " />
                        </a>
                     <a href="https://www.facebook.com/thejnci">
                        <img class="small_margin" alt="Connect with us on Facebook!"
                             src="http://www.oxfordjournals.org/our_journals/phisci/facebook.png"
                             style="vertical-align: top; float: left; " />
                        </a>
                     
                     <p>
                        <br />
                        <br />
                        
                     </p>
                     
                  </div>
                  
                  <div class="feature separator_after">
                     
                     <h3>Editor-in-Chief</h3>
                     
                     <p>Carmen J. Allegra</p>
                     
                     <ul class="emphasised">
                        <li>
                           <a href="http://www.oxfordjournals.org/our_journals/jnci/editorial_board.html"
                              rel=""
                              title="View full editorial board">View full editorial board</a>
                           
                        </li>
                     </ul>
                     
                  </div>
                  
                  <div class="feature separator_after">
                     
                     <h3>Impact factor: 12.583</h3>
                     
                     <h3 class="five_year">5-Yr impact factor: 13.584</h3>
                     
                  </div>
                  
                  <div class="feature">
                     
                     <h3>For the Media</h3>
                     
                     <ul class="emphasised">
                        <li>
                           <a href="http://www.oxfordjournals.org/our_journals/jnci/press_room.html" rel=""
                              title="JNCI PRESS ROOM">JNCI PRESS ROOM</a>
                           
                        </li>
                     </ul>
                     
                  </div>
                  
                  <div class="feature">
                     
                     <h2 id="for_authors" title="For Authors"><span>For Authors</span></h2>
                     
                     <ul class="emphasised">
                        <li>
                           <a href="http://www.oxfordjournals.org/our_journals/jnci/for_authors/index.html"
                              rel=""
                              title="Instructions to authors">Instructions to authors</a>
                           
                        </li>
                        <li>
                           <a href="http://www.oxfordjournals.org/access_purchase/self-archiving_policyb.html"
                              rel=""
                              title="Self Archiving/Public Access Policy">Self Archiving/Public Access Policy</a>
                           
                        </li>
                     </ul>
                     <a href="http://www.oxfordjournals.org/oxfordopen/ ">
                        <img alt="Open access options for authors - visit Oxford Open"
                             src="http://www.oxfordjournals.org/resource/image/promos/oxford_open_small.gif" />
                        </a>
                     <a href="http://www.oxfordjournals.org/oxfordopen/funder_policies/">
                        <img alt="RCUK Wellcome Trust Open Access"
                             src="http://www.oxfordjournals.org/resource/image/wellcome-trust-180x100.jpg" />
                        </a>
                     
                     <p>Open access options for authors - visit <a href="http://www.oxfordjournals.org/oxfordopen/">Oxford Open</a>
                        
                     </p>
                     <a href="http://publicaccess.nih.gov/submit_process_journals.htm">
                        <img alt="PMC Logo" src="http://www.oxfordjournals.org/resource/image/pmc-logo.gif" />
                        </a>
                     
                     <ul class="emphasised">
                        <li>
                           <a href="http://publicaccess.nih.gov/submit_process_journals.htm" rel=""
                              title="This journal enables compliance with the NIH Public Access Policy">This journal enables compliance with the NIH Public Access Policy</a>
                           
                        </li>
                     </ul>
                     
                  </div>
                  
                  <div class="feature">
                     
                     <h2 id="alerting_services" title="Alerting Services"><span>Alerting Services</span></h2>
                     
                     <ul class="emphasised">
                        <li>
                           <a href="/cgi/alerts/etoc" rel="" title="Email table of contents">Email table of contents</a>
                           
                        </li>
                        <li>
                           <a href="/cgi/alerts/etoc" rel="" title="Email Advance Access">Email Advance Access</a>
                           
                        </li>
                        <li>
                           <a href="http://jnci.oxfordjournals.org/help/citetrack/index.dtl" rel=""
                              title="CiteTrack">CiteTrack</a>
                           
                        </li>
                        <li>
                           <a href="/rss" rel="" title="XML RSS feed">XML RSS feed</a>
                           
                        </li>
                     </ul>
                     
                  </div>
                  
                  <div class="feature">
                     
                     <h2 id="corporate_services" title="Corporate Services"><span>Corporate Services</span></h2>
                     
                     <ul class="emphasised">
                        <li>
                           <a href="http://www.oxfordjournals.org/corporate_services/advertising.html" rel=""
                              title="Advertising sales">Advertising sales</a>
                           
                        </li>
                        <li>
                           <a href="http://www.oxfordjournals.org/corporate_services/reprints.html" rel=""
                              title="Reprints">Reprints</a>
                           
                        </li>
                        <li>
                           <a href="http://www.oxfordjournals.org/corporate_services/classifiedadinprint.html"
                              rel=""
                              title="Classified Advertising">Classified Advertising</a>
                           
                        </li>
                     </ul>
                     
                  </div>
                  
               </div>
               <script type="text/javascript">var taxonomies = ["MED00300"];</script>
               </div>
            
            <div class="most-links-box js-marker">
               
               <div class="most-header">
                  
                  <h3>Most</h3>
                  
               </div>
               
               <ul>
                  <li class="most-cur-sel">
                     <h4>Most Read</h4>
                     	  
                     <div class="most-list">
                        	    
                        <ol>
                           <li class="first-item"><a href="http://jnci.oxfordjournals.org/cgi/content/short/92/6/443?rss=1&amp;ssource=mfr">Breast Density and Cancer Risk: What Is the Relationship?</a></li>
                           <li><a href="http://jnci.oxfordjournals.org/cgi/content/short/90/9/713?rss=1&amp;ssource=mfr">The Female Prostate</a></li>
                           <li><a href="http://jnci.oxfordjournals.org/cgi/content/short/91/14/1194?rss=1&amp;ssource=mfr">Tobacco Smoke Carcinogens and Lung Cancer</a></li>
                           <li><a href="http://jnci.oxfordjournals.org/cgi/content/short/107/6/djv048?rss=1&amp;ssource=mfr">Annual Report to the Nation on the Status of Cancer, 1975-2011, Featuring Incidence of Breast Cancer Subtypes by Race/Ethnicity,
                                 Poverty, and State</a></li>
                           <li class="last-item"><a href="http://jnci.oxfordjournals.org/cgi/content/short/105/23/1799?rss=1&amp;ssource=mfr">Elevated Plasma Vitamin B12 Levels as a Marker for Cancer: A Population-Based Cohort Study</a></li>
                        </ol>
                        	    <a href="http://jnci.oxfordjournals.org/reports/mfr1.dtl" class="view-all">» View all Most Read articles</a>
                        	  
                     </div>
                     	
                  </li>
                  <li>
                     <h4>Most Cited</h4>
                     	
                     <div class="most-list">
                        	  
                        <ol>
                           <li class="first-item"><a href="http://jnci.oxfordjournals.org/cgi/content/short/92/3/205?rss=1&amp;ssource=mfc">New Guidelines to Evaluate the Response to Treatment in Solid Tumors</a></li>
                           <li><a href="http://jnci.oxfordjournals.org/cgi/content/short/90/18/1371?rss=1&amp;ssource=mfc">Tamoxifen for Prevention of Breast Cancer: Report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study</a></li>
                           <li><a href="http://jnci.oxfordjournals.org/cgi/content/short/85/5/365?rss=1&amp;ssource=mfc">The European Organization for Research and Treatment of Cancer QLQ-C30: A Quality-of-Life Instrument for Use in International
                                 Clinical Trials in Oncology</a></li>
                           <li><a href="http://jnci.oxfordjournals.org/cgi/content/short/82/13/1107?rss=1&amp;ssource=mfc">New Colorimetric Cytotoxicity Assay for Anticancer-Drug Screening</a></li>
                           <li class="last-item"><a href="http://jnci.oxfordjournals.org/cgi/content/short/82/1/4?rss=1&amp;ssource=mfc">What Is the Evidence That Tumors Are Angiogenesis Dependent?</a></li>
                        </ol>
                        	  <a href="http://jnci.oxfordjournals.org/reports/mfc1.dtl" class="view-all">» View all Most Cited articles</a>
                        	
                     </div>
                     
                  </li>
               </ul>
               
            </div>
            
            
            
         </div>
         
         
         
         <div id="oas_bottom" class="ad_hidden">
            <iframe id="id_advertframe_bottom"
                    src="/resource/htmlfiles/advert.html?p=Bottom&amp;u=jnci.oxfordjournals.org/content/99/11/847.full"
                    width="0"
                    height="0"
                    frameborder="0"
                    scrolling="no"
                    class="resize_ad"></iframe>
            
         </div>
         
         
         
         
         
         
         <div id="secondary_footer">
            
            <div id="issn">Online ISSN 1460-2105 - Print ISSN 0027-8874</div>
            
            
            <div id="copyright"><a href="http://www.oxfordjournals.org/our_journals/terms.html">Copyright ©</a> 
               <span>2015</span> Oxford University Press
               
            </div>
            
         </div>
         
         <div id="primary_footer">
            
            <div id="site_logo">
               <strong><span>Oxford Journals</span></strong>
               <em><span>Oxford University Press</span></em>
               
            </div>
            
            
            <div id="third_nav">
               
               <ul>
                  <li><a href="http://www.oxfordjournals.org/site_map.html">Site Map</a></li>
                  <li><a href="http://www.oxfordjournals.org/legal/privacy_policy.html">Privacy Policy</a></li>
                  <li><a href="http://global.oup.com/cookiepolicy/?siteid=journals">Cookie Policy</a></li>
                  <li><a href="http://www.oxfordjournals.org/legal/legal_notices.html">Legal Notices</a></li>
                  <li><a href="http://www.oxfordjournals.org/faq/">Frequently Asked Questions</a></li>
               </ul>
               
            </div>
            
            
            <div id="other_oup_sites">
               
               <form action="http://www.oxfordjournals.org/service/redirect">
                  <div>
                     <label for="site_list">Other Oxford University Press sites:</label>
                     <select name="url" id="site_list">
                        <option value="http://www.oup.com">Oxford University Press</option>
                        <option value="http://www.oxfordjournals.org/china/">Oxford Journals China</option>
                        <option value="http://www.oxfordjournals.org/japan/">Oxford Journals Japan</option>
                        <option value="http://www.oup.com/uk/academic">Academic &amp; Professional books</option>
                        <option value="http://www.oup.com/oxed">Children's &amp; Schools Books</option>
                        <option value="http://www.oup.com/uk/dictionaries">Dictionaries &amp; Reference</option>
                        <option value="http://www.oup.co.uk/newdnb/">Dictionary of National Biography</option>
                        <option value="http://www.oup.com/uk/digital_reference">Digital Reference</option>
                        <option value="http://www.oup.com/elt/">English Language Teaching</option>
                        <option value="http://www.oup.com/uk/textbooks">Higher Education Textbooks</option>
                        <option value="http://www.oup.co.uk/ieu/">International Education Unit</option>
                        <option value="http://www.oup.com/uk/law">Law</option>
                        <option value="http://www.oup.com/uk/medicine">Medicine</option>
                        <option value="http://www.oup.com/uk/music">Music</option>
                        <option value="http://www.oup.com/online">Online Products &amp; Publishing</option>
                        <option value="http://oxfordbibliographiesonline.com">Oxford Bibliographies Online</option>
                        <option value="http://oxforddictionaries.com">Oxford Dictionaries Online</option>
                        <option value="http://www.oed.com">Oxford English Dictionary</option>
                        <option value="http://www.oxfordlanguagedictionaries.com">Oxford Language Dictionaries Online</option>
                        <option value="http://www.oxfordscholarship.com">Oxford Scholarship Online</option>
                        <option value="http://www.oup.com/uk/reference">Reference</option>
                        <option value="http://www.oup.com/uk/rights">Rights and Permissions</option>
                        <option value="http://www.oup.com/uk/booksellers">Resources for Retailers &amp; Wholesalers</option>
                        <option value="http://www.oup.com/uk/corporate">Resources for the Healthcare Industry</option>
                        <option value="http://www.oup.com/vsi">Very Short Introductions</option>
                        <option value="http://www.oup.com/worldsclassics">World's Classics</option></select>
                     
                     <input type="image" src="/resource/image/buttons/go.gif" alt="Go"
                            class="inline_button" />
                     
                  </div>
               </form>
               
            </div>
            
         </div>
         <script type="text/javascript"
                 src="http://gab.cookie.oup.com/aws-cookie/oup.cookiepolicy.pack.js"
                 defer="defer"></script>
         
         <script defer="defer"
                 src="http://oi-underbar.ifactory.com/underbar/js/jquery-ui.min.js"
                 type="text/javascript"></script>
         <script defer="defer"
                 src="http://oi-underbar.ifactory.com/underbar/js/jcarousellite.js"
                 type="text/javascript"></script>
         <script defer="defer"
                 src="http://oi-underbar.ifactory.com/underbar/js/pf_oiunderbarinit.js"
                 type="text/javascript"></script>
         <script defer="defer" src="/resource/js/underbar_local.js" type="text/javascript"></script>
         <script defer="defer" type="text/javascript">
    function fnc_onDomLoaded() {
        var query_context = getQueryContext();
        PF_initOIUnderbar(query_context,":QS:default","","JRN"); 
        PF_insertOIUnderbar(0);
    };
    if (window.addEventListener) { 
        window.addEventListener('load', fnc_onDomLoaded, false); 
    } else if (window.attachEvent) { 
        window.attachEvent('onload', fnc_onDomLoaded); 
    } 
</script>
         <noscript><img src="//ouptag.scholarlyiq.com/ntpagetag.gif?js=0" height="1" width="1"
                 border="0"
                 hspace="0"
                 vspace="0"
                 alt="" /></noscript><script type="text/javascript" src="//ouptag.scholarlyiq.com/ntpagetag.js"></script><script type="text/javascript">
        var gaJsHost = (("https:" == document.location.protocol) ? "https://ssl." : "http://www.");
        document.write(unescape("%3Cscript src='" + gaJsHost + "google-analytics.com/ga.js' type='text/javascript'%3E%3C/script%3E"));
        </script><script type="text/javascript">
        try {
        var pageTracker = _gat._getTracker("UA-189672-16");
        pageTracker._setDomainName(".oxfordjournals.org");
        pageTracker._trackPageview();
        } catch(err) {}
        </script></div>
   </body>
</html>